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Abstract 
Under normal conditions macrophages provide immune surveillance and host 
defense in tissues to maintain homeostasis. However, upon sensing changes in the 
microenvironment, macrophages become activated, undergoing a morphological 
and functional switch. ActiǀatioŶ of these Đells is Ŷot aŶ ͞all-or-ŶoŶe͟ pƌoĐess, ďut 
rather a continuum characterized by a wide spectrum of molecular and functional 
pheŶotǇpes ƌaŶgiŶg fƌoŵ the ͞ĐlassiĐal͟ Mϭ aĐtiǀated pheŶotǇpe, ǁith a highlǇ pƌo-
iŶflaŵŵatoƌǇ pƌofile, to the ͞alteƌŶatiǀe͟ MϮ pheŶotǇpe, assoĐiated ǁith a 
beneficial, less inflammatory, protective profile. The possibility to promote a 
macrophage protective phenotype has therefore become a therapeutic goal in the 
treatment of inflammatory conditions, and the identification of factors that control 
cell activation is currently an area of active research. Most studies in the field so far 
have been performed using primary mouse macrophages or macrophage cell lines, 
and a variety of monocyte differentiation protocols and macrophage activation 
markers are used by different labs. Moreover, the pharmacological control of 
human macrophage polarized activation has not been extensively explored. A 
number of natural and synthetic compounds, including chalcones and curcumin, the 
major active component isolated from the turmeric plant Curcuma longa, have 
been shown to induce effects on macrophage function (including antioxidant, anti-
microbial, anti-carcinogenic and anti-inflammatory action) through multiple 
pharmacological mechanisms, including interference with TLR4 signaling. On these 
grounds, the specific aims of the present thesis were: a) to test cell models and 
differentiation protocols other than spontaneous blood-derived macrophage 
differentiation, namely the THP-1 cell line and CSF-1-driven differentiation, 
respectively; b) to profile the cytokine pattern into the culture medium, and c) to 
determine the modulation of phenotypic markers by pharmacological agents, 
namely curcumin derivatives known to suppress microglial activation through 
reduced production and release of pro-inflammatory mediators, as well as the 
underlying mechanisms of action. 
Macrophages were differentiated from human PBMCs isolated by density gradient 
centrifugation, and cultured in RPMI 1640 medium with 10% FBS with CSF-1 for 6 
days to obtain resting macrophages (M0). Classical (M1) and alternative (M2) 
phenotypes were generated using specific cytokines (0.1-1 µg/ml LPS or 20 ng/ml IL-
4 plus 5 ng/ml IL-13, respectively) in the presence or absence of curcumin analogues 
or dexamethasone used a reference compound. Macrophage phenotypes were 
determined by flow cytometry using fluorocrome-labeled antibodies. Gene 
expression was analysed using qRT-PCR. The composition of macrophage 
conditioned media (MCM) was assessed with the Luminex technology. Curcumin 
analogues were kindly provided by Dr. Federica Belluti (University of Bologna). 
When M2 polarization was induced with IL-4/IL-13 for 24h, we observed increased 
expression of M2 markers compared with M0. In terms of gene expression analysis 
of the CSF-1 driven macrophages, as expected, M1-polarized macrophages after 6 
or 48 h showed higher mRNA levels of TNF-α aŶd IL-ϭβ Đoŵpaƌed ǁith MϬ. The 
increase in mRNA was more marked after 48 h for all genes except TNF-α, ǁhiĐh 
rose more sharply after 6 h. The anti-inflammatory cytokine IL-10 mRNA was 
unexpectedly more abundant in M1- than in M2-polarized macrophages, and 
peaked after 6 h. Compared with M0, M2 MCM showed higher levels of anti-
inflammatory cytokines including CCL22 and IL-4. In contrast, M1 MCM was 
associated with higher levels of IL-ϭα, IL-ϭβ, IL-6, IL-8, MCP-1, VEGF and TNF-α. 
Treatment with the curcumin analogue GG9 as well as CLI095, an inhibitor of TLR4 
intracellular domain, reversed the LPS-induced up-regulation of CD80
+
 (M1) cells. A 
similar effect was maintained with the double positive CD80
+
/CCR2
+
 population. 
Unlike dexamethasone, which increased the percentage of CD163
+
 (M2) cells, the 
curcumin analogue GG9 did not affect M2 markers. Treatment with GG9 
significantly blocked IL-ϭβ ĐǇtokiŶe pƌoduĐtioŶ at the Đell-bound level, in the protein 
lysate and in the medium. By contrast, curcumin and GG6 did not affect the levels 
of intra- and extracellular IL-ϭβ. To iŶǀestigate iŶtƌaĐellulaƌ sigŶaliŶg pathǁaǇs 
involved in cell activation, we performed Western blot analysis of factors involved in 
the NF-κB pathǁaǇ. AĐtiǀatioŶ ǁith LP“ sigŶifiĐaŶtlǇ deĐƌeased the ƌelatiǀe 
eǆpƌessioŶ of IκB-α. BǇ ĐoŶtƌast, ĐuƌĐuŵiŶ aŶd GGϲ ǁeƌe aďle to ƌestoƌe IκB-α 
amounts as did CLI095, whereas no effect was induced by GG9 treatment. 
Therefore, M1 and M2 macrophages showed specific profiles of gene expression 
and surface markers, which were modulated by pharmacological treatment with 
dexamethasone or a curcumin analogue. Overall, these data suggest that polarized 
activation protocols may have an impact on the functional status of macrophages 
and are critical to further investigate pharmacological macrophage targeting. 
  
Riassunto 
In condizioni normali i macrofagi sono i responsabili della risposta immunitaria e 
della difesa dell’ospite peƌ ŵaŶteŶeƌe l’oŵeostasi tissutale. IŶ seguito a stiŵoli 
presenti nel microambiente, i macrofagi possono attivarsi, andando incontro a uno 
switch moƌfologiĐo e fuŶzioŶale. L’attiǀazioŶe di Ƌueste Đellule ŶoŶ è uŶ pƌoĐesso 
͞tutto o Ŷulla͟ ŵa piuttosto uŶ continuum caratterizzato da un ampio spettro di 
fenotipi molecolari e funzionali, i cui estremi sono rappresentati dal fenotipo 
defiŶito ͞ĐlassiĐo͟ o M1, con un profilo pro-iŶfiaŵŵatoƌio, e da Ƌuello ͞alteƌŶatiǀo͟ 
o M2, anti-infiammatorio e protettivo. La possibilità di promuovere un fenotipo 
macrofagico protettivo sta diventando un obiettivo terapeutico nel trattamento 
delle condizioni infiammatorie e l’ideŶtifiĐazioŶe di fattoƌi Đhe ƌegolaŶo l’attiǀazioŶe 
Đellulaƌe è attualŵeŶte uŶ’aƌea di ƌiĐeƌĐa ŵolto attiǀa. La ŵaggioƌ paƌte degli studi 
in questo ambito sono stati condotti utilizzando culture primarie di macrofagi di 
topo o linee cellulari; inoltre, i vari laboratori usano protocolli diversi di 
isolamento/differenziamento dei monociti e marcatori diversi di attivazione. Inoltre, 
il ĐoŶtƌollo faƌŵaĐologiĐo dell’attiǀazioŶe ŵaĐƌofagiĐa ŶoŶ è aŶĐoƌa stato iŶdagato 
sufficientemente. Una serie di composti naturali e sintetici, ad esempio il calcone e 
la curcumina, il principale componente attivo della Curcuma longa (pianta nota per 
effetti anti-ossidanti, anti-microbici, anti-tumorali e anti-infiammatori) hanno 
dimostrato un effetto sulla funzione dei macrofagi, agendo attraverso diversi 
meccanismi farmacologici, ad esempio interferendo con il signaling del TLR4. Sulla 
base di queste premesse, gli scopi specifici di questo lavoro di tesi erano: a) testare 
un modello cellulare e un protocollo di differenziamento diverso da quello 
spontaneo, in particolare la linea cellulare monocitaria THP-1 e il differenziamento 
in presenza di CSF-1; b) determinare il profilo delle citochine presenti nel terreno di 
coltura e c) determinare la modulazione dei marcatori dei fenotipi di attivazione da 
parte di agenti farmacologici, in particolare da derivati di sintesi della curcumina, 
Ŷoti peƌ la loƌo ĐapaĐità di ŵodulaƌe l’attiǀazioŶe di Đellule ŵuƌiŶe di ŵiĐƌoglia 
attraverso la riduzione della produzione e rilascio di mediatori pro-infiammatori. 
I macrofagi sono stati differenziati a partire dai linfo-monociti umani isolati tramite 
gradiente di densità e coltivati in terreno RPMI + 10% FBS con aggiunta di CSF-1 per 
6 giorni, ottenendo così macrofagi in condizioni basali (M0). Il fenotipo classico (M1) 
e il fenotipo alternativo (M2) sono stati ottenuti incubando i macrofagi M0 
rispettivamente con 0.1-1 µg/ml LPS e IL-4 20 ng/ml + IL-13 5 ng/ml, in presenza o 
assenza di analoghi della curcumina, desametazone o CLI095, un inibitore del 
dominio intracellulare del TLR4 (questi ultimi utilizzati come composti di 
riferimento). I fenotipi macrofagici sono stati determinati tramite citofluorimetria 
utilizzaŶdo speĐifiĐi aŶtiĐoƌpi legati a fluoƌofoƌi. L’espƌessioŶe geŶiĐa è stata 
valutata tramite qRT-PCR. La composizione dei terreni condizionati (macrophage 
conditioned media, MCM) è stata valutata con la tecnologia Luminex. Gli analoghi 
della curcumina sono stati gentilmente forniti dalla Prof.ssa Federica Belluti 
(Università di Bologna). In seguito a polarizzazione per 24 h con IL-4/IL-13 abbiamo 
osseƌǀato uŶ auŵeŶto dell’espƌessioŶe dei ŵaƌĐatoƌi MϮ ƌispetto a MϬ. Peƌ ƋuaŶto 
ƌiguaƌda l’espƌessioŶe geŶiĐa di ŵaĐƌofagi diffeƌeŶziati ĐoŶ C“F-1, come atteso, i 
macrofagi M1 dopo 6 o 48h presentavano livelli superiori di mRNA per TNF-α e IL-1β 
ƌispetto a MϬ. L’auŵeŶto dell’ŵRNA eƌa più ŵaƌĐato dopo ϰϴ h peƌ tutti i geŶi 
tranne TNF-α, Đhe ƌaggiuŶgeǀa il piĐĐo a ϲh. L’ŵRNA della ĐitoĐhiŶa aŶti-
infiammatoria IL-10 inaspettatamente era più espresso nei macrofagi M1 rispetto a 
MϮ e ƌaggiuŶgeǀa il piĐĐo dopo ϲ h. Rispetto a MϬ, l’MCM MϮ eƌa Đaƌatteƌizzato da 
alti livelli di citochine anti-infiammatorie tra le quali CCL22 e IL-4. Al contrario, 
l’MCM Mϭ pƌeseŶtaǀa liǀelli eleǀati di IL-1α, IL-1β, IL-6, IL-8, MCP-1, VEGF e TNF-α. Il 
pre-tƌattaŵeŶto ĐoŶ l’aŶalogo della ĐuƌĐuŵiŶa GGϵ e il ĐoŶtƌollo positiǀo CLIϬϵϱ ha 
pƌeǀeŶuto l’auŵeŶto iŶdotto da LP“ del ŵaƌĐatoƌe Mϭ CDϴϬ. UŶ effetto siŵile è 
mantenuto anche sulla frazione di cellule a doppia marcatura CD80
+
/CCR2
+
. Al 
contrario del desametazone, che aumenta la percentuale di cellule CD163
+
 (M2), il 
GG9 non ha modulato i marcatori M2. Il trattamento con GG9 ha bloccato in 
maniera significativa la produzione di IL-1β valutata come citochina cell-bound, nel 
lisato Đellulaƌe o ƌilasĐiata Ŷel teƌƌeŶo di Đoltuƌa. Al ĐoŶtƌaƌio, l’aŶalogo GGϲ ŶoŶ ha 
modificato i livelli di IL-1β intra- ed extra-cellulare. Per indagare più nel dettaglio le 
ǀie di segŶale ĐoiŶǀolte Ŷell’attiǀazioŶe di Ƌueste Đellule, aďďiaŵo effettuato analisi 
Western Blot di fattori coinvolti nella via di segnale di NF-κB. L’attiǀazioŶe ĐoŶ LP“ 
ha ƌidotto sigŶifiĐatiǀaŵeŶte l’espƌessioŶe ƌelatiǀa di IκB-α. Curcumina, GG6 e 
CLI095 hanno riportato IκB-α ai livelli di controllo, a differenza del GG9 che non 
ŵodifiĐaǀa sigŶifiĐatiǀaŵeŶte l’espƌessioŶe di Ƌuesta pƌoteiŶa. 
Pertanto, i macrofagi M1 ed M2 presentano specifici profili di attivazione genica e di 
marcatori di superficie che possono essere modulati in seguito a trattamento 
farmacologico con desametazone o analoghi della curcumina. Nel complesso, questi 
dati suggeriscono che protocolli di attivazione macrofagica possono avere un 
impatto sullo stato funzionale di queste cellule e sono fondamentali per definire 
nuove strategie di targeting farmacologico nei macrofagi umani. 
  
 
 
 
 
1. Introduction 
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1.1 IMMUNE SYSTEM: THE ESSENTIALS 
The immune system is a network of cells, tissues and organs that work together to 
defeŶd the ďodǇ agaiŶst attaĐks ďǇ ͞foƌeigŶ͟ iŶǀadeƌs: these aƌe pƌiŵaƌilǇ ŵiĐƌoďes, 
i.e. tiny organisms such as bacteria, parasites and fungi that can cause infections. 
The inflammatory response usually has two components: an innate non adaptive 
response and an adaptive (acquired or specific) immunologic response (Delves and 
Roitt, 2000). Innate immunity, also called natural immunity, consists of several 
ďodǇ͛s oǁŶ ŵeĐhaŶisŵs ǁhiĐh aƌe ƌapidlǇ aďle to ĐouŶteƌaĐt pathogeŶs iŶǀasioŶ. 
The main components of the innate immunity are: 
1. physical/chemical barriers such as cough reflex, enzymes in tears and skin 
oils, mucus, skin and stomach acid that keep out harmful materials from 
entering the body, thus forming the first line of defense in the immune 
response; 
2. phagocytic cells, such as neutrophils and macrophages, and cells with 
cytotoxic activity, such as natural killer (NK). The phagocytic cells use a 
combination of degrading enzymes, antimicrobial peptides and reactive 
oxygen species to kill the invading microorganisms. In addition, they release 
signaling molecules that trigger an inflammatory response and begin to 
marshal the forces of the adaptive immune system; 
3. circulating proteins, such as those included in the complement system or 
other mediators of the immune response; 
4. several proteins, such as cytokines and chemokines, which regulate and 
coordinate many functions performed by cells of innate immunity. 
In addition to innate immunity, exposure to infectious agents initiate more complex 
mechanisms belonging to the so-called acquired immunity, whose power and 
defensive ability increases with each subsequent exposure to the same pathogen. 
The cumulative effects triggered by the immune system to defend the body against 
the etiologic agent are known as inflammation. In the long term, however, the lack 
of resolution and the chronicity of inflammatory responses may contribute to the 
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development of a number of diseases including, among others, atherosclerosis 
(Moore et al., 2013) and obesity (Han et al., 2013). 
 
1.2. THE MONOCYTE-MACROPHAGE SYSTEM 
Monocytes, macrophages and dendritic cells (DCs) are part of the ͞mononuclear 
phagocyte system͟ (MPS), a body-wide specialized system of phagocytic cells (van 
Furth et al., 1972). This system function is the innate immune response, in support 
of the adaptive immune response and in maintenance of tissue homeostasis. The 
established concept of the MPS has been used to unify such a diverse cell type as 
one functional entity.  
According to this concept, monocytes developing in the bone marrow (BM) 
continuously colonize different tissues and mature into macrophages in situ. 
However, this concept has been challenged recently and thought to be an 
oversimplification. The first evidence that tissue macrophages can develop from 
embryonic sources and bypass monocytic intermediates came from microglia-
resident macrophages in brain parenchyma. Based on the fate mapping mouse, 
microglia were shown to be derived from embryonic day 7.5 (E7.5) yolk sac (YS) 
precursors (Ginhoux et al., 2010). Furthermore, based again on fate mapping 
mouse, YS origin was generalized to macrophages in other tissues including 
epidermis, liver, spleen, lung, pancreas, and kidney (Schulz et al., 2012). In a study 
by Schulz et al. (2012), the authors noted that mouse tissue macrophages can 
consist of different pools of cells based on F4/80 and CD11b expression: F4/80
hi
 
macrophages were postulated to be derived from YS precursors that are able to 
maintain their numbers in situ (resident), while CD11b
hi
 macrophages were thought 
to be replaced continuously by BM-generated (infiltrating) monocytes. In 
subsequent studies, F4/80
hi
 resident macrophages were proposed to originate from 
YS-derived erythro-myeloid progenitors (Gomez Perdiguero et al., 2015; Sheng et 
al., 2015). 
Thus, the model of the MPS needs to be extended to include not just monocytes as 
a major source of tissue macrophages but to highlight the prenatal origins of many 
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populations, some of which involve cells arising from a distinct YS-embryonic 
macrophage lineage. The current view is that tissue-resident macrophages 
comprise cell populations derived from three sources: yolk sac, fetal liver and 
hematopoietic stem cells in the bone marrow (Fig. 1.1). The relative contributions 
of embryonic versus hematopoietic sources to resident macrophages vary by tissue, 
with some tissues being populated mainly by YS-derived macrophages (for example, 
Langerhans cells in the skin and microglia in the brain) and other tissues having 
mainly BM–derived macrophages (for example, the intestine). Another major 
insight has been provided by the realization that YS–derived macrophages (and 
presumably fetal liver–derived macrophages) can be maintained for the lifespan of 
the organism by continuous self-renewal. It is not yet clear whether all tissue-
resident macrophages can enter the cell cycle or whether small fractions of these 
self-renew by asymmetric cell division (similar to stem cells). This distinction is 
important because of its implications for understanding the functional 
heterogeneity of tissue macrophages and the lack of distinct phenotypic markers 
able to identify unique subsets (Okabe and Medzhitov, 2015). 
 
Figure 1.1: The mononuclear phagocytic system in adults derives from at least three sources. The 
first is the yolk sac (YS) that results in progenitors that populate all tissues and their progeny persist 
throughout life as F4/80 bright resident macrophages. The second from the fetal liver is less well 
defined but seems to contribute to adult LCs perhaps through a progenitor derived from the YS. The 
third lineage derives from the bone marrow (BM) to give circulating monocytes and their progeny 
F4/80
low
 macrophages and DCs. From Wynn et al., 2013. 
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A more recent idea proposed that ontogenic distinction is relevant to disease 
pathogenesis, as it is apparent that the functions of BM-derived monocytes can be 
very different from those of tissue-resident macrophages in the same inflammatory 
environment. The two cell types have distinct expansion mechanisms and distinct 
functions in the brain during experimental autoimmune encephalitis. Infiltrating 
monocytes are recruited via extravasation from blood vessels and produce 
inflammatory mediators important for disease progression but do not persist after 
the resolution of inflammation. In contrast, activated resident microglia cells 
proliferate locally, persist and return to quiescence following remission. Thus, it 
might be inaccurate to describe tissue-ƌesideŶt ŵaĐƌophages as alǁaǇs ďeiŶg ͚aŶti-
iŶflaŵŵatoƌǇ͛ iŶ ĐoŶtƌast to passeŶgeƌ ŵaĐƌophages that aƌe alǁaǇs ͚pƌo-
iŶflaŵŵatoƌǇ͛. A connection between ontogenesis and function could be possible 
but the respective roles of tissue-resident macrophages and passenger 
macrophages remain to be studied in detail, characterizing the underlying 
molecular mechanisms involved (Gomez Perdiguero and Geissmann, 2015). 
1.2.1 Monocyte heterogeneity 
Monocytes are a critical part of the MPS and are involved in many diseases with an 
inflammatory component, such as infection, cardiovascular disease, type-1 diabetes 
and cancer. Blood monocytes represent a large pool of scavenger and potential 
effector cells inside blood vessels in homeostasis as well as during inflammatory 
processes. In mammals, monocytes also represent accessory cells, which can link 
inflammation and the innate defense against microorganisms to adaptive immune 
responses. Indeed, the best known function of monocytes is as a considerable 
systemic reservoir of myeloid precursors for the renewal of some tissue 
macrophages and antigen-presenting DCs (Auffray et al., 2009). Several lines of 
evidence have indicated that the role of monocytes, both in the control of 
pathogens and in the pathophysiology of inflammation, can be attributed to 
different functional groups. Therefore, the issue of heterogeneity of monocytes 
becomes relevant for human health. Monocytes are equipped with a large array of 
scavenger receptors that recognize microorganisms but also lipids and dying cells, 
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and stimulated monocytes can produce large quantities of effector molecules, such 
as reactive oxygen species (ROS), prostaglandins, cytokines including tumor necrosis 
factor (TNF)-α, interleukin (IL)-ϭβ, IL-8, IL-6 and IL-10, vascular endothelial growth 
factor (VEGF), and proteolytic enzymes involved in the defense against pathogens 
and in the pathogenesis of several inflammatory diseases, including arthritis and 
atherosclerosis. Although the heterogeneity of monocytes is not fully understood, 
one theory suggests that monocytes continue to grow and mature into the blood 
and tissues, and can be recruited at different stages during the maturation process 
(Fig. 1.2). The state of maturation at the time they leave the blood stream can, in 
fact, define their function. 
 
Figure 1.2: Cells of the mononuclear phagocytic system (MPS) arise in the bone marrow, where they 
develop from pluripotent stem cells (PPSCs) through various multipotent progenitor stages: 
granulocyte/macrophage colony-forming unit (GM-CFU) to macrophage CFU (M-CFU) to monoblast 
to pro-monocyte. In the bone, osteoclast progenitors develop from these cells under the influence of 
colony-stimulating factor 1 (CSF1), and these differentiate in response to receptor activator of 
nuclear factor-κB ligaŶd ;‘ANKLͿ iŶto osteoĐlasts. Another population differentiates into bone 
marrow macrophages also in response to CSF1, and the ex vivo culture of these cells and their 
progenitors is often used for macrophage studies. In addition, monocytes are released into the 
circulation. From Pollard et al., 2009. 
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The existence of at least two phenotypically and functionally distinct monocyte 
subsets has been demonstrated in humans and mice, which suggests evolutionary 
conservation of monocyte heterogeneity (Gautier et al., 2009). Monocytes 
represent about 10% of leukocytes in human blood and 4% of leukocytes in mouse 
blood. Studies examining homing and differentiation of mouse monocytes in vivo 
have identified two major monocyte subpopulations based on their expression 
profile of the surface marker Ly6C (or GR-1), and chemokine receptors such as CCR2 
(CCL2 chemokine receptor) and CX3CR1 (CX3C chemokine receptor 1, also known as 
fractalkine receptor; Hristov and Weber, 2011). Ly6C is a useful marker to 
distinguish different populations of murine monocytes and macrophages: it belongs 
to a family of cell surface phosphatidylinositol-anchored glycoproteins expressed in 
varying degree in leukocytes, although its function remains unknown (Brancato and 
Albina, 2011; Motwani and Gilroy, 2015). Inflammatory monocytes, characterized 
as Ly6C
high
/CX3CR1
low
/CCR2
+
 cells, migrate into sites of inflammation during the 
early phase of the response to injury. A second population of murine monocytes, 
ofteŶ ƌefeƌƌed to as ͞ƌesideŶt͟ oƌ ͞patƌolliŶg͟, aƌe defiŶed as LǇϲClow 
CX3CR1
hi
/CCR2
-
 cells, which egress the circulation into wounds and other sites of 
inflammation to resolve the immune response (Hristov and Weber, 2011; Ginhoux 
and Jung, 2014). In mice, classical and non-classical monocyte frequency is 
approximately 1:1 (Fig. 1.3). 
 
Figure 1.3: Circulating monocyte heterogeneity. Peripheral blood circulating monocytes are present 
iŶ tǁo distiŶĐt populatioŶs, Đalled ͞ĐlassiĐal͟ aŶd ͞ŶoŶ-ĐlassiĐal͟ ǁith diffeƌeŶt ƌelatiǀe aďuŶdaŶĐe 
(expressed in %) and characterized by different pattern of surface markers. This classification has 
been demonstrated both in mice (lower portion of the image) and in humans (upper portion). From 
Gautier et al., 2009. 
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In humans, monocytes were initially identified by their expression of large amounts 
of CD14 (a cluster of differentiation which is part of the lipopolysaccharide 
receptor). However, the subsequent identification of differential expression of 
antigenic markers showed that monocytes in human peripheral blood are 
heterogeneous, and this provided the first clues to the differential physiological 
activities of monocyte subsets. Differential expression of CD14 and CD16 (also 
kŶoǁŶ as FCγ‘IIIͿ alloǁed huŵaŶ ŵoŶoĐǇtes to ďe distiŶguished iŶto tǁo sepaƌate 
subsets, similar to monocyte classification in mice: as depicted in Fig. 3, 
CD14
hi
/CD16
-
 cells, which are often called classical monocytes, represent 80% to 
90% of circulating monocytes and express high levels of the chemokine receptor 
CCR2 and low levels of CX3CR1. Conversely, CD14
low
/CD16
+
 cells, or non-classical 
monocytes, have a CX3CR1
high
/CCR2
low
 phenotype (Gordon and Taylor, 2005; 
Mantovani et al., 2009; Ziegler-Heitbrock et al., 2010). 
1.2.2 Macrophage plasticity and polarization 
A keǇ featuƌe of ŵaĐƌophages is theiƌ aďilitǇ to ͚tailoƌ͛ theiƌ ƌespoŶses aĐĐoƌdiŶg to 
environmental stimuli. Upon encountering pathogens, macrophages express pro-
inflammatory cytokines and reactive oxygen and nitrogen species that aid 
antimicrobial and immune activation functions needed to kill and control 
pathogens. By contrast, homeostatic signals induce macrophages to adopt 
phenotypes linked with tissue remodeling and repair (Glass and Natoli, 2015). 
Because the signals encountered by macrophages are different and also dynamic, 
macrophages not only respond with phenotypes but also can switch from one 
͚fuŶĐtioŶal͛ pheŶotǇpe to aŶotheƌ. HeŶĐe, diǀeƌsitǇ aŶd plastiĐitǇ of pheŶotǇpe aŶd 
function are characteristic features of macrophages (Gordon and Taylor, 2005). In 
macrophages, inflammatory stimuli such as lipopolysaccharide (LPS) and interferon 
(IFN)-γ induce an inflammatory phenotype that promotes TH1 effector response and 
antimicrobial and tumoricidal properties. LPS/IFNγ activated cells are efficient 
producers of effectors molecules (reactive nitrogen and oxygen intermediates) and 
pro-inflammatory cytokines, such as IL-6, IL-ϭβ aŶd TNF-α, induce up-regulation of 
molecules associated with antigen presentation, such as major histocompatibility 
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complex (MHC) class II and the co-stimulatory molecules CD40, CD80 and CD86 
(Mantovani et al., 2013). MaĐƌophages ǁith this pheŶotǇpe aƌe Đalled ͚ĐlassiĐallǇ 
actiǀated͛ ŵaĐƌophages or M1. In contrast, stimulation of macrophages with 
cytokines such as IL-4 or IL-ϭϯ leads to aŶ ͚alteƌŶatiǀe͛ aĐtiǀatioŶ state or M2, 
characterized by low levels of inflammatory cytokines such as IL-12 and IL-23, and 
high levels of the anti-inflammatory cytokine IL-10, with variable capacity to 
produce chemokines such as CCL17, CCL18 and CCL22, and generally have high 
levels of scavenger, galactose-type and mannose receptors (MR or CD206). In 
general, IL-4/IL-13 activated cells take part in polarized TH2 responses, parasite 
clearance, the dampening of inflammation, the promotion of tissue remodeling, 
angiogenesis, tumor progression and immunoregulation (Biswas and Mantovani, 
2010). 
However, macrophages in many other homeostatic or pathological situations do not 
show a clear M1 or M2 phenotype, or show phenotypic plasticity during disease 
progression, clearly indicating that the dichotomous M1-M2 model is insufficient to 
describe macrophage activation. In this context, Xue and collegues (2014) recently 
generated a resource data set to assess transcriptional regulation during human 
macrophage activation by comparing a diverse set of stimuli on a single microarray 
platform under highly standardized conditions. Network modeling of this data set 
allow us to eǆteŶd the ĐuƌƌeŶt Mϭ ǀeƌsus MϮ polaƌizatioŶ ŵodel to a ͚͚speĐtƌuŵ 
ŵodel͛͛ ǁith distiŶĐt ŵaĐƌophage aĐtiǀatioŶ pƌogƌaŵs. Moreover, a new way of 
looking at macrophage activation is to consider a multidimensional model of 
activation, which integrates the signals to which macrophages are exposed in their 
specific microenvironments (Fig. 1.4; Davies and Taylor, 2015).  
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Figure 1.4: A multidimensional view of macrophage activation that is influenced by their ontogeny. 
Macrophages in various tissues are yolk sac derived (microglia of the brain), fetal liver monocyte 
derived (alveolar macrophages in the lung and Kupffer cells in the liver for example), derived from 
both yolk sac macrophages and fetal liver monocytes (Langerhans cells in the epidermis) or replaced 
after birth with adult bone marrow monocytes (gut, heart and dermal macrophages). Furthermore, 
tissue-specific environmental signals are important drivers of macrophage activation during adult 
tissue homeostasis. Once a tissue insult occurs and stress signals are elevated in the tissue 
environment, these new signals are further integrated in the respective program. From Ginhoux et 
al., 2015. 
Okabe and Medzhitov (2015) in their recent review suggested that many aspects of 
the development and function of tissue-resident macrophages can best be 
described by a variation on two important factors: first, migratory progenitor cells 
populate diffeƌeŶt tissues, ǁheƌe theǇ ŵaǇ ƌeĐeiǀe ͚tissue-ideŶtitǇ͛ sigŶals that 
promote their local differentiation into tissue-resident macrophages. Second, 
resident macrophages receive signals that indicate local functional demands, which 
induce diverse functional programs and associated phenotypes of macrophages, as 
well as their precise location and number within tissues. Thus, the phenotypes of 
tissue-resident macrophages are mostly a combination of differentiation and 
polarization programs.  
In this continuum of plastic activation states a specific functional phenotype is 
associated with the expression of a wide range of particular surface proteins that 
can be used for macrophage identification. Unfortunately, there is diversity of 
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macrophage activation across species, and markers that are appropriate in mouse 
macrophages are not necessarily conserved in human cells (Murray et al., 2014) 
(Fig. 1.5). For example, in agreement with literature data, M1 macrophages can be 
identified by their surface expression of the scavenger receptor CD68 (a 
glycoprotein that binds LDL), CCR2, receptor for the chemokine CCL2 also known as 
MCP-1 (monocyte chemoattractant protein 1), and the co-stimulatory molecules 
CD80 and CD86; by contrast, M2 macrophages typically express CD163 (the 
scavenger receptor for the hemoglobin-haptoglobin complex), the mannose 
receptor CD206 (which recognizes pathogens that have mannose on their surface) 
and the chemokine-X3C receptor-1 (CX3CR1), also known as fractalkine receptor 
(Ambarus et al., 2012a; Tedesco et al., 2015). 
 
Figure 1.5: Marker systems for activated macrophages. Shown are functional subdivisions according 
to stimulation of mouse CSF-1 macrophages or human monocyte-derived CSF-1 macrophages with 
the existing M1-M2 spectrum concept. Stimulation conditions are IL-4, immune complexes (Ic), IL-10, 
glucocorticoids (GC) with transforming growth factor β (TGF-β), glucocorticoids alone, LPS, LPS and 
IFNγ, and IFNγ alone. Marker data were drawn from a wide range of published and unpublished data 
fƌoŵ the authoƌs͛ laďoƌatoƌies aŶd ƌepƌeseŶt a staƌtiŶg consensus. An asterisk indicates 
corroboration of human IL-4 genes by deep sequencing. From Murray et al., 2014. 
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In vitro activation of monocyte-derived macrophages using cytokines, growth 
factors, prostaglandins, glucocorticoids and toll-like receptor (TLR) agonists, alone 
or in combination, represents a potential therapeutic approach to prevent the 
development of disease and promote immune tolerance in mice and humans. 
 
1.3. ROLE OF M1 AND M2 MACROPHAEGS IN CHRONIC INFLAMMATORY DISEASES 
Macrophages are central to tissue development, homeostasis and inflammation, 
but they also contribute to a broad spectrum of inflammatory pathologies and thus 
represent key therapeutic targets (Ginhoux et al., 2015). The dynamic balance 
between M1 and M2 phenotypes requires a fine regulation, otherwise the resulting 
loss of immune regulation contributes to the development and/or exacerbation of 
chronic inflammatory diseases, such as atherosclerosis (Pello et al., 2011; Chinetti-
Gbauguidi et al., 2015), rheumatoid arthritis, obesity (Kammoun et al., 2014) and 
insulin resistance (Fig. 1.6; Fadini et al., 2013). This occurs with combined deficits in 
the number and/or function of multiple types of regulatory cells leading to the 
inability to sustain M2 macrophages. Although what causes these 
immunoregulatory mechanisms to fail is unknown, inappropriate stimulation of pro-
inflammatory cells could be one of the inciting events for chronic systemic 
inflammation (Han and Levings, 2013). 
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Figure 1.6: Macrophages play many developmental roles shaping the architecture of tissues ranging 
from the brain to bone to the mammary gland. Once development is over, macrophages modulate 
homeostasis and normal physiology through regulating diverse activities including metabolism and 
neural connectivity and by detecting damage. These trophic and regulatory roles, however, are often 
subverted by continuous insult and macrophages contribute to many diseases that are often 
associated with aging. From Wynn et al., 2013. 
1.3.1 Atherosclerosis 
Macrophage accumulation within the vascular wall is a hallmark of atherosclerosis. 
In atherosclerotic lesions, macrophages respond to various environmental stimuli, 
such as modified lipids, cytokines, and senescent erythrocytes, which can modify 
their functional phenotypes. In particular, the disease is characterized by intimal 
lesions of the vessel wall, and a switch from M2 to M1 macrophage phenotype has 
been hypothesized to occur during atherogenesis, similarly to what happens in 
obese subjects. Indeed, macrophages are involved in all key stages of 
atherosclerosis development including early inflammatory injury, development of 
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fatty streaks and finally plaque rupture. Several studies on human atherosclerotic 
plaques demonstrate that the relative proportions of macrophage subsets within a 
plaque might be an indicator of plaque phenotype and stability (Chinetti-Gbauguidi 
et al., 2015). During the development and progression of atherosclerosis, 
macrophages are exposed to many different environmental cues, including pro- and 
anti-inflammatory cytokines, cholesterol, oxidized lipids, and heme that influence 
gene expression and regulate macrophage function (Leitinger and Schulman, 2013). 
Cholesterol crystals for example, found in advanced atherosclerotic lesions, were 
recently shown to be also present at early stages of atherosclerotic lesions. In LPS-
primed human peripheral blood mononuclear cells and in vivo in mice, cholesterol 
crystals activate the caspase-1-activating-NLRP3 inflammasome, thus inducing the 
cleavage and the release of IL-1 family cytokines (including IL-ϭβ and IL-18; Duewell 
et al., 2010). This observation suggests that cholesterol crystals act as a M1 pro-
inflammatory stimulus (Colin et al., 2014). Another important event acting in the 
atherosclerotic lesions is the rupture of microvessels that releases erythrocytes, 
which can be phagocytosed by macrophages, leading to an increase in iron content 
and release of heme associated with oxidized lipid deposition. Hemoglobin- 
stimulated macrophages are characterized by high levels of CD206 and CD163 and 
by the secretion of anti-inflammatory cytokines, such as IL-10 (Chinetti-Gbauguidi et 
al., 2015). Other factors, such as cytokines, senescent cells and growth factors that 
are present in the plaque, can influence macrophages activation.  
Besides the total number of macrophages, histological analysis revealed a specific 
spatial distribution of distinct macrophage subpopulations in human atherosclerotic 
plaques (Fig. 1.7). In the human plaque shoulder, the site most prone to plaque 
rupture, M1 macrophages represent the principal population, while the repartition 
of M1/M2 macrophages is similar in fibrous cap regions. Thus, potential deleterious 
effects of M1 macrophages may be counteracted by protective pro-fibrotic and 
tissue repair effects of M2 macrophages in the fibrous cap, while the limited 
number of M2 macrophages cannot balance the M1-mediated effects in the plaque 
shoulder. Interestingly, M2 macrophages are the predominant population in the 
adventitia of the human atherosclerotic plaque, suggesting that these M2 
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macrophages may have migrated from the surrounding perivascular adipose tissue 
(Colin et al., 2014). 
The identification of biological stimuli that can modulate macrophages activation 
could lead to the development of novel therapeutic approaches for the treatment 
of atherosclerosis (Chinetti-Gbauguidi et al., 2015). 
 
 
Figure 1.7: Localization of macrophage subsets in human atherosclerotic lesions. M1 macrophages 
are predominantly found in the plaque shoulder and lipid core, whereas M2 macrophages are most 
abundant in the adventitia and areas of neovascularization, which also contain iron deposits. Fibrous 
caps contain similar amounts of both macrophage subsets. From Chinetti-Gbauguidi et al., 2015. 
1.3.2 Obesity and type-2 diabetes 
Obesity-associated adipose tissue inflammation appears to be caused by infiltration 
of inflammatory immune cells and a parallel loss or functional reprogramming of 
immunoregulatory cells. Together, these changes lead to a variety of positive 
feedback pathways that not only sustain chronic inflammation, but also contribute 
to the development of insulin resistance and type-2 diabetes. The key point is that 
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the inflammation accompanying obesity is distinctly different to that of acute 
inflammation, as the inflammatory stimulus fails to be resolved (Kammoun et al., 
2014). The general view in obesity is that there is an imbalance in the ratio of 
M1/M2 macrophages, with pro-inflammatory macrophages being enhanced 
compared with anti-inflammatory macrophages being down-regulated, leading to 
chronic inflammation and the propagation of metabolic dysfunction. In a healthy 
state M2 macrophages are induced by peroxisome proliferator activated receptor 
(PPAR)-γ sigŶaliŶg aŶd ŵaiŶtaiŶ adipoĐǇte fuŶĐtioŶ, iŶsuliŶ seŶsitiǀitǇ aŶd gluĐose 
tolerance, which can prevent the development of diet-induced obesity and type-2 
diabetes (Murray and Wynn, 2011). However, weight gain induces local 
inflammation and chemokine production to promote recruitment of circulating pro-
inflammatory (Ly6C
hi
) monocytes. Recruited monocytes differentiate into an M1 
macrophage phenotype and their accumulation leads to an imbalance between M1 
and M2 macrophages. Increased cytokine production from M1 macrophages and/or 
reduced anti-inflammatory signals from the M2 macrophages promotes adipose 
tissue dysfunction and impairs glucose tolerance (Fig. 1.8; Kraakman et al., 2014). 
Evidence for the detrimental role of M1 macrophages in promoting adipose tissue 
insulin resistance is accumulating. A recent study on novel phenotypes of blood 
monocytes shows that type-2 diabetes is also associated with a marked reduction of 
the anti-inflammatory M2 phenotype. Fadini and colleagues (2013) found that 
hypercholesterolemia and type-2 diabetes are characterized by a marked reduction 
in M2 cells while M1 cells are unchanged compared with controls; as a result, the 
M1/M2 polarization ratio is increased in diabetes. As type-2 diabetes is considered 
a pro-inflammatory condition, it is striking that the monocyte polarization 
imbalance is attributable to a defect in anti-inflammatory rather than an excess of 
pro-inflammatory cells (Fadini et al., 2013). This observation is in line, however, 
with the view that diabetes is a disease of impaired damage control (Schaper and 
Havekes, 2012), in which injury is worsened by defective repair. 
17 
 
 
Figure 1.8: In the lean healthy adipose tissue, M2 like macrophages self-maintain through 
proliferation. They ensure tissue remodeling and pathogen screening. In the obese adipose tissue, 
over nutrition leads to larger adipocytes, which coupled with cellular stress, and promotes the 
development of a pro-inflammatory environment. In this context, M1-like macrophages start to 
accumulate. From Kraakman et al., 2014. 
 
1.4. IN VITRO MODELS OF MACROPHAGE ACTIVATION 
Macrophages, derived from monocyte precursors, undergo specific differentiation 
depending on the local tissue environment. The various macrophage functions are 
linked to the type of receptor interaction on the macrophage surface and, crucially, 
to the cytokine milieu in the microenvironment (Ginhoux and Jung, 2014). Human 
monocytes can be obtained from three different main sources: whole blood, cord 
blood, or the human monocyte cell line THP-1. Cord blood monocytes are selected 
as CD14
+
 from the mononuclear stem cells (Jaatinen and Laine, 2007). Conversely, 
THP-1 cells are derived from human acute monocytic leukemia and can be 
differentiated to macrophages by adding phorbol ester (TPA) into the culture 
medium (Tjiu et al., 2009). The most commonly used are circulating monocytes that 
can be obtained following different approaches; the isolation process of 
mononuclear cells from whole blood affects the subsequent differentiation method 
to obtain mature macrophages. Peripheral blood mononuclear cells (PBMCs) can be 
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isolated from whole blood samples by density gradient centrifugation, for example 
using Ficoll-Paque
TM
, a polymer that stratifies the different blood components 
according to their specific weight. Then PBMCs can be stratified upon hyper-
osmotic Percoll (another synthetic polymer), and pure monocytes are obtained 
after a second gradient centrifugation. With this method monocyte purity is 95-98% 
(Repnik et al., 2003). Alternatively, purified monocytes can be obtained through 
magnetic cell sorting using specific CD14-labeled magnetic beads (Bender et al., 
2004; Martinez et al., 2013). This method usually allows obtaining a 90% monocyte 
(CD14
+
) pure suspension. Working with highly pure monocytes population requires 
exogenous growth factors and/or cytokines (i.e. colony-stimulating factor-1 (CSF-1) 
or granulocyte macrophages colony-stimulating factor (GM-CSF)) in the culture 
medium for survival of monocytes (Jaguin et al., 2013).  
Nature of polarizing agents and exposure time appear to be crucial, especially when 
testing the potential impact of pharmacological interventions. For this reason a 
panel of experts published experimental guidelines for macrophage activation and 
polarization (Murray et al., 2014), trying to clarify something that in literature is 
very contentious and confusing. If seeded after Ficoll separation, human monocyte-
derived macrophages are able to spontaneously differentiate in vitro in the absence 
of growth factors other than those contained in animal or human serum (Ambarus 
et al., 2012a; Eligini et al., 2013; Tedesco et al., 2015). Spontaneous macrophage 
differentiation may be related to the relative abundance of TH2 cytokines secreted 
by CD3
+
 lymphocytes early in culture before their detachment and/or by the 
fraction of lymphocytes which could be persistent in culture during the whole 
differentiation period. By contrast, working with pure monocyte populations (using 
Percoll-or beads-based methods) requires differentiation stimuli like CSF-1 or GM-
CSF. There is no compelling evidence that these two factors could influence the 
subsequent macrophages activation (Murray et al., 2014). It is also important to 
define the mediators, used alone or in various combination, that are used for the 
generation of activated macrophages. Furthermore, Murray et al. proposed that 
researchers describe also stimulation scenarios and adopt a nomenclature linked to 
the activation standards (i.e. M(LPS) or M(IL-4)). Developing gold standard 
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differentiation/activation protocols would be useful to compare data from different 
research groups and perform screens of macrophage activation-modifying 
pharmacological agents. 
 
1.5. PHARMACOLOGICAL CONTROL OF MACROPHAGE POLARIZATION 
Specific macrophage-target therapies are now taking the first steps into clinical 
investigations. In addition, therapeutic approaches not originally designed as 
macrophage oriented or specific have been found to affect macrophage activation 
and polarization (Sica and Mantovani, 2012). Therefore, it is relevant to identify 
novel mechanisms for the pharmacological control of human macrophage 
polarization. For instance, although it is well established that glucocorticoids induce 
multiple effects on several immune cell types, glucocorticoid treatment of human 
monocytes does not cause a global suppression of monocytic effector functions but 
rather results in differentiation of a specific anti-inflammatory phenotype which 
seems to be involved in resolution of inflammation (Ehrchen et al., 2007). Similarly, 
Vallelian et al. (2010) found that glucocorticoid treatment of monocytes in vitro and 
in patients on glucocorticoid-pulse therapy polarizes monocytes into a 
M2/alternatively activated phenotype with high Hb-scavenger receptor (CD163) 
expression and enhanced Hb clearance and detoxification. A positive regulation of 
CD163 following dexamethasone treatment was demonstrated in recent studies in 
human macrophages (Ambarus et al., 2012a; Tedesco et al., 2015). Opposite effects 
on macrophage polarization were observed on human monocyte-derived 
macrophages challenged with the immunosuppressant agent rapamycin after 
polarization. The presence of rapamycin induces apoptosis in M2 but not in M1 
macrophages, and enhances M1 surface markers and pro-inflammatory cytokines 
production together with a reduction of typical M2 markers (Mercalli et al., 2013). 
Statins are thought to reduce vascular inflammation through lipid-independent 
mechanism. Van der Meij et al. (2013) evaluated the anti-inflammatory potency of 
simvastatin and atorvastatin in patients on therapy for at least 6 weeks. Both statins 
equally effectively and dose-dependently shifted macrophage polarization towards 
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a M2 phenotype and reduced vascular wall nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) activity in abdominal aorta aneurysms 
samples, thus diminishing inflammatory responses. The inhibition of the NF-κB 
pathway was demonstrated also in monocytes treated in vitro with rosuvastatin 
(Margaritis et al., 2014). PPA‘γ agoŶists ;thiazolidiŶdioŶesͿ haǀe loŶg ďeeŶ used iŶ 
the treatment of diabetes. The evidence linking PPA‘γ to MϮ polaƌizatioŶ provides 
new insights into their mode of action. It has been demonstrated that rosiglitazone 
markedly increases the number of macrophages in adipose tissue of obesity-
induced mice. In particular, markers for classically activated macrophages including 
IL-18 are down-regulated, whereas markers characteristic for alternatively activated 
macrophages (arginase 1, IL-10) are up-regulated by rosiglitazone (Stienstra et al., 
2008). Interestingly, a positive correlation between the expression of M2 markers 
aŶd PPA‘γ has ďeeŶ shoǁŶ iŶ huŵaŶ atheƌosĐleƌotiĐ lesioŶs. Moƌeoǀeƌ, PPA‘γ 
activation primes primary human monocytes into alternative M2 macrophages with 
anti-inflammatory properties (Bouhlel et al., 2007). 
New insights come from microRNA (miRNA) studies. miRNAs have recently emerged 
as a major class of gene expression regulators linked to most biological functions. In 
particular, the miRNA let-7c, which is overexpressed in M2 compared with M1 
subset of mouse bone marrow-derived macrophages, plays an important role in 
regulating macrophage polarization (Banerjee et al., 2013). Furthermore, a 
procedure for generating pharmaceutical-grade human regulatory macrophages has 
been recently developed and approved for a clinical trial as an adjunct 
immunosuppressive agent in living-donor kidney transplantation (clinicaltrials.gov: 
NCT02085629). To date, two patients have been treated with human regulatory 
macrophages preparations, both of whom have not undergone any rejection 
episode after more than 6 years after transplantation (Hutchinson et al., 2011). 
Therefore, several medications appear to have an impact on the functional status of 
macrophages; however, the extent to which their effect on macrophages explains 
their clinical efficacy remains to be defined. The identification of mechanisms and 
molecules associated with macrophage plasticity and polarized activation provides a 
basis for macrophage-centered diagnostic and therapeutic strategies. 
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In the next section a short account is provided on the potential of novel analogues 
of natural compounds to modulate human macrophage activation and polarization. 
In particular, although anti-inflammatory effects of curcumin have been reported in 
a variety of experimental models (Aggarwal and Harikumar, 2009; Shehzad et al., 
2013), the possibility that curcumin and/or analogues thereof affect human 
macrophage activation has not been explored in much detail. 
 
1.6. CURCUMIN 
Turmeric (haldi), a rhizome of Curcuma longa, is a flavorful yellow-orange spice. Its 
plant is 1 meter in height and has lance-shaped leaves and spikes of yellow flowers 
that grow in a fleshy rhizome or in underground stem. An orange pulp contained 
inside the rhizome constitutes the source of turmeric medicinal powder (Nagpal 
and Sood, 2013). Curcumin (1,7-bis(hydroxyl-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione) is the most important active polyphenolic ingredient responsible for the 
biological activity of turmeric. It was first isolated from the drug in 1815 by Vogel 
and Pelletier, but its structure was not elucidated until 1913 (Fig. 1.9). Curcumin is 
insoluble in water, but soluble in ethanol and acetone. Components of tumeric are 
named curcuminoids and the naturally occurring ratios of curcuminoids in curcumin 
are about 5% bisdemethoxy curcumin, 15% demethoxy curcumin, and 80% 
curcumin. The various components of the turmeric have their medical importance 
(Alok et al., 2015). Curcumin has been used extensively in ayurvedic medicine for 
centuries and various pharmacological actions of curcumin have been investigated 
by researchers worldwide, as it appears to be nontoxic and shows a variety of 
possible therapeutic indications (Nagpal and Sood, 2013; Ghosh et al., 2015). 
 
Figure 1.9: The chemical structure of curcumin, first described by Milobedzka et al. in 1910 
22 
 
The wound healing potential of curcumin is attributed to biochemical effects such 
as its anti-inflammatory, anti-infectious and anti-oxidant activities (Akbik et al., 
2014), but the mechanisms of action of this natural compound will be discuss more 
in details in Section 7 below. 
1.6.1 Curcumin analogues 
Poor bioavailability, rapid metabolism and adverse effects observed in some studies 
are major problems that limited curcumin clinical investigation and application 
(Maheshwari et al., 2006; Anand et al., 2008). For this reason, in the present work 
we decided to assess the pharmacological profile of two additional curcumin-based 
analogues, called GG6 and GG9. The molecular structures of GG6 and GG9 are 
shown in Fig. 1.10. The aim of designing and synthetizing a library of curcumin-
based analogues is to perform a structure-activity relationship study and to 
determine the essential chemical features required to modulate the selected 
targets involved in inflammatory processes and diseases (i.e. TLR-4 activation). To 
this end, the aryl side rings of this scaffold was decorated with selected substituents 
and modifications were performed on the central α, β-unsaturated carbonyl 
fragment in order to assess its importance for biological activity. Published synthetic 
procedures for curcumin derivatives include the Pabon reaction, in which selected 
aldehydes were reacted with 2,4-pentanedione under well-defined reaction 
condition (Pabon, 1964). This procedure proved to be suitable for a parallel 
chemical synthesis approach, which allows one to obtain libraries of analogues. In 
particular, the commercial availability of large numbers of synthetic intermediates 
(aldehydes and acetophenones) permitted the incorporation of a broad chemical 
diversity for the newly synthetized molecules. 
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Figure 1.10: Molecular structure of synthetic curcumin-based anaogues GG6 and GG9. These 
molecules were kindly provided by Prof. Federica Belluti (University of Bologna). 
 
1.7. CURCUMIN AND THE IMMUNE SYSTEM 
Curcumin has been used for its various therapeutic properties for thousands of 
years. It is clear from various studies that curcumin, like many natural products, has 
many biological activities and is relatively safe and well-tolerated. It is also nontoxic 
even at doses up to 8 g per day. The effects of curcumin are mediated partially 
through its antioxidant and anti-inflammatory properties. At the same time it can 
also modulate multiple signaling molecules like transcription factors, enzymes and 
secondary messengers, thereby controlling expression of many genes, and is 
potentially effective in the case of many disease conditions associated with 
impaired regulation of such signaling pathways (Fig. 1.11; Ghosh et al., 2015). 
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Figure 1.11: Various cellular signaling molecules modulated by curcumin. From Ghosh et al., 2015. 
With regard to the physicochemical and antioxidant activities of curcumin, the keto-
enol-enolate equilibrium of the heptadienone moiety has been reported to be 
essential (Tocharus et al., 2012). The central CH2 group adjacent to the highly 
activated carbon atom in the heptadienone link may be the actual reaction site 
because the C-H bonds on this carbon should be very weak due to massive 
delocalization of the unpaired electron on the adjacent oxygen atoms. Besides, the 
phenolic OH is the most preferable group for the proton loss from the one-electron 
oxidized species. As the resultant phenoxyl radical is stabilized by delocalization of 
electrons, the ability for curcumin to scavenge the oxidizing free radicals is greatly 
increased. The resonance-stabilized radicals can undergo further loss of the second 
hydrogen atom from the second phenolic OH group, producing a diradical. This 
diradical may be converted into stable products like quinones or undergo cleavage 
to produce smaller phenols like ferulic acid. The theoretical data on atomic charge 
and the bond energy calculation for H atom dissociation channel from various sites 
of curcumin and its radicals do support the experimental observations (Priyadarsini 
et al., 2003; Menon and Sudherr, 2007; Ghosh et al., 2015). 
Curcumin is a well-known anti-inflammatory agent. Joe et al. (2004) thoroughly 
reviewed the numerous mechanisms by which curcumin modulates inflammation. 
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Most notably, curcumin was shown to inhibit the production of TNF-α aŶd IL-1β, 
two main cytokines released from monocytes and macrophages that play important 
roles in the regulation of inflammatory responses. The natural compound 
modulates TNF-α expression by affecting the methylation pattern of TNF-α 
promoter (Reuter et al., 2011), activating Nrf2/HO-1 and down-regulating the 
expression of TNF-α, IL-1β, IL-6 and IL-8 (Priyanka et al., 2014; Liu et al., 2015). Of 
eƋual iŵpoƌtaŶĐe is ĐuƌĐuŵiŶ͛s aďilitǇ to iŶhiďit the aĐtiǀitǇ of NF-κB, a 
transcriptional factor that regulates many genes involved in the initiation of 
inflammatory responses. NF-κB is normally activated by various kinases (AKT, PI3K, 
IKK), and curcumin affects various pathways implicated in its activation, as shown in 
Fig. 1.12 (Akbik et al., 2014).  
 
Figure 1.12: Curcumin interferes with inflammatory pathways by blocking the transcription factor 
NF-κB. The Ŷuŵďeƌs ϭ, Ϯ aŶd ϯ ƌepƌeseŶt the pathǁaǇs inhibited by curcumin. From Aknik et al., 
2014. 
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With regard to NF-κB receptor-dependent activation, Youn et al. (2006) described 
the inhibition of TLR4 homodimerization by curcumin. Activation of TLRs, a major 
family of pattern recognition receptors, provides an important step by which 
immune cells initiate inflammatory response through recognizing both invading 
pathogens and endogenous danger signals (Lien and Golenbock, 2003). In 
particular, TLR4, in association with its co-receptor myeloid differentiation protein-2 
(MD-2), is responsible for the recognition of LPS, the major Gram-negative bacteria 
wall component, and represents a primary mediator of immune response. LPS 
induces the activation of NF-κB through both MyD88- and TRIF-dependent 
pathways, and the activation of IRF3 through TRIF-dependent pathway. Curcumin 
inhibits LPS-induced NF-κB and IRF3 activation in RAW264.7 cells (Youn et al., 2006). 
Furthermore, curcumin has been shown to suppress the activation of NF-κB induced 
by various pro-inflammatory stimuli by inhibiting IKKβ kinase activity (Jobin et al., 
1999), suggesting that the molecular targets of curcumin include the TLR4 receptor 
complex in addition to IKKβ. Youn et al. described in more detail the molecular 
mechanisms by which curcumin acts on NF-κB pathway: the compound inhibits the 
dimerization of TLR4 induced by LPS, and its α,β-unsaturated carbonyl group can 
react with –SH group in cysteine in the activation loop of IKKβ, inhibiting the kinase 
activity of IKKβ ;YouŶ et al., ϮϬϬϲͿ. More recently, Zhou et al. (2015) confirmed 
these data. Therefore, the main effect of curcumin appears to be on LPS activation, 
especially on the expression of M1 markers (such as CD80) that are modulated 
through the NF-κB pathway (Lien and Golembock, 2003).  
In the literature curcumin is also reported to affect M2 activation: in particular, one 
study showed that curcumin could not only directly induce the polarization of 
macrophages to M2 phenotype, but also promote conversion of macrophages from 
M1 to M2 phenotype (Chen et al., 2014). More recently, Gao et al. (2015) 
demonstrated that curcumin induces macrophage M2 polarization by increasing the 
production of IL-4 and/or IL-13 in a STAT6-dependent manner. They also observed 
that curcumin attenuates experimental autoimmune myocarditis (EAM) by 
decreasing the infiltration of inflammatory macrophages and inducing shift of 
macrophages in myocardium from both M0 and M1 to M2 phenotype. Based on 
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these observations and recent findings on microglia activation (Tocharus et al., 
2012; Mercanti et al., 2014), curcumin and its analogues represent promising lead 
compounds targeting immune cells activation. The possibility to promote a 
macrophage protective phenotype has therefore become a therapeutic goal in the 
treatment of inflammatory conditions, and the identification of factors that control 
cell activation is currently an area of active research. 
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2. Aim 
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New data are redefining macrophages as diverse, polyfunctional and plastic cells 
that respond to the needs of the tissue at steady state and during disturbed 
homeostasis. Inflammation plays a critical role in the onset and progression of 
degenerative diseases, and is characterized by activation of tissue-resident 
macrophages as well as monocyte-derived macrophages that originate and renew 
from the adult bone marrow. Under normal conditions these cells provide immune 
surveillance and host defense in the tissues to maintain homeostasis. However, 
upon sensing changes in the microenvironment, macrophages become activated, 
undergoing a morphological and functional switch (Sica and Mantovani, 2012). 
AĐtiǀatioŶ of these Đells is Ŷot aŶ ͞all-or-ŶoŶe͟ pƌoĐess, ďut ƌather a continuum 
characterized by a wide spectrum of molecular and functional phenotypes ranging 
fƌoŵ the ͞ĐlassiĐal͟ Mϭ aĐtiǀated pheŶotǇpe, ǁith a highlǇ pƌo-inflammatory 
pƌofile, to the ͞alteƌŶatiǀe͟ MϮ pheŶotǇpe, assoĐiated ǁith a ďeŶefiĐial, less 
inflammatory, protective profile (Toniolo et al., 2014). However, recent advances in 
macrophage development, activation and functional diversity shape the 
understanding of macrophage biology and drive new models of activation and 
classification, away from the classical dichotomous categorization as M1 and M2 
macrophages and into more complex models that can accommodate the continuum 
of transcriptional and functional states observed in vivo. Various pathologies, 
ranging from obesity to autoimmunity and neurodegenerative disease, have been 
linked to the dysregulation of macrophage function.  
The diversity of terminology and inconsistent use of markers to describe 
macrophage activation impedes reaching a consensus in this research field. In 
particular, a critical issue is the diversity in macrophage activation across species. 
Similarly, cell lines (i.e. THP-1) as opposed to primary cultures are widely used as 
macrophage models. CSF-1-cultured macrophages from murine bone marrow and 
human peripheral-blood monocytes remain the predominant in vitro systems used 
for generating macrophages. In general, the culture conditions for generating the 
two paradigmatic in vitro M1 and M2 populations are straightforward, i.e., post 
differentiation stimulation with IFN-γ oƌ IL-4. Given the lack of gold standards for 
M1 or M2 activation, we previously demonstrated that (a) the cell population 
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resulting from spontaneous differentiation has predominance of the M2 over M1 
phenotype as measured by flow cytometry, and (b) the expression of M1 vs. M2 
markers is not mutually exclusive (Tedesco et al., 2015). However, patterns of 
macrophage activation may differ based on experimental protocols used by labs 
active in the field. Therefore, differentiation and activation protocols appear to be 
crucial, as shown e.g. by recent guidelines and comparison studies (Vogel et al., 
2014; Murray et al., 2014).  
This is especially relevant when testing the potential impact of pharmacological 
interventions targeting macrophage function. In fact, there is wide interest in the 
development of diagnostic and therapeutic approaches targeting polarized 
inflammation and macrophage activation phenotypes. For instance, by employing a 
ǀaƌietǇ of eǆpeƌiŵeŶtal desigŶs, PPA‘γ agoŶists ;Bouhlel et al., 2007) and statins 
(van der Meij et al., 2013) have been shown to promote M2-like polarization, 
whereas glucocorticoids induce an M2c activation state (Mantovani et al., 2004; 
Ambarus et al., 2012a). However, translation of this knowledge basis to clinical 
application may be hampered by the plurality of experimental protocols associated 
with the remarkable plasticity of cells of the mononuclear phagocyte lineage. 
Deployment of therapeutic macrophage modulators therefore requires that 
standards be translatable across disciplines so that pharmaceutical and regulatory 
bodies can draw meaningful comparisons in terms of diagnostic or efficacy metrics. 
On these grounds, the specific aims of the present thesis were: a) to test cell 
models and differentiation protocols other than spontaneous blood-derived 
macrophage differentiation (Tedesco et al., 2015), namely the THP-1 cell line and 
CSF-1-driven differentiation, respectively; b) to profile the cytokine pattern into the 
culture medium, and c) to determine the modulation of phenotypic markers by 
pharmacological agents, namely curcumin derivatives known to suppress microglial 
activation through reduced production and release of pro-inflammatory mediators 
(Mercanti et al., 2014), as well as the underlying mechanisms of action. 
  
31 
 
 
 
 
 
 
3. Materials and Methods 
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3.1. MATERIALS  
RPMI 1640 was purchased from LONZA (Basel, Switzerland), antibiotics solution 
(100 U/ml penicillin and 100 µg/mL streptomycin) from Invitrogen Inc. (Carlsbad, 
CA, US). Monoclonal antibodies anti-human COX-1 and COX-2 were from Cayman 
Chemical (Ann Arbor, MI, US), and anti-human IκB-α and GAPDH were from Cell 
Signaling (Danvers, MA, US). HRP-conjugated secondary antibodies were purchased 
from Vector (Peterborough, UK). anti-CCR2 mAb, anti-CD163 mAb, anti-IL-ϭβ ŵAď, 
brefeldin, Fix and Perm buffer solutions were from eBioscience/Affymetrix (Santa 
Clara, CA, US); anti-CD80 mAb, anti-CD206 mAb from BD Biosciences Pharmigen 
(San Diego, CA, US). RevertAid Reverse Transcriptase, random examers, nucleotides, 
RNAse inhibitors and Max SYBR Green PCR Master Mix were purchased from 
Thermo Fisher (Waltham, MA, US). Complete protease inhibitor mixture was from 
Roche (Mannhein, Germany). Hematoxylin and eosin, fetal bovine serum (FBS), 
Ficoll-Paque (density 1.077±0.001), Percoll, dexamethasone, curcumin, CLI095, 
lipopolysaccharide (LPS), skim milk powder as well as other analytic grade chemical 
agents were purchased from Sigma-Aldrich (St. Louis, MO, USA). IFN-γ, IL-4, IL-13 
and CSF-1 were from Immuno Tools GmbH (Friesoythe, Germany). Curcumin 
analogues were kindly provided by Dr. Federica Belluti (Department of Pharmacy 
and Biotechnology, University of Bologna, Italy). 
Experimental protocol 
The experimental protocol is outlined in Fig. 3.1: 
 
Figure 3.1. A schematic line drawing the experimental approach 
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3.2. CELL CULTURE 
Human peripheral mononuclear cells (PBMCs) were isolated from buffy coats 
provided by the Transfusion Unit at Padua University Hospital. The buffy coat is the 
fraction of an anticoagulated sample that contains most of the white blood cells and 
platelets following density gradient centrifugation of the blood. Blood samples from 
20 healthy donors were processed.  
3.2.1 Ficoll gradient and spontaneous differentiation 
PBMCs were isolated by density gradient centrifugation using a Ficoll-Paque 
solution, a hydrophilic polysaccharide commonly used in biology laboratories to 
separate blood to its components (density 1.077±0.001). Ficoll-Paque was placed at 
the bottom of a conical tube, and blood was then slowly layered above it in a 
20:15ml ratio. After being centrifuged at 600g for 30 min, different layers were 
visible in the conical tube, from top to bottom: plasma and other constituents, a 
white layer of mono-nuclear cells called buffy coat (PBMC/MNC), Ficoll-Paque, and 
erythrocytes & granulocytes. PBMCs were harvested using a sterile Pasteur pipette 
and transferred to a new centrifuge tube. To reduce platelet contamination, cells 
were washed twice with PBS + 5mM EDTA at 300g for 15 min. Cells were seeded at 
the density of 15x10
6
 cells in 100-mm dishes and 6x10
6
 cells in 60-mm dishes in 
serum-free RPMI 1640 medium supplemented with 100 U/ml penicillin and 100 
µg/mL streptomycin. After 2h, non-adherent cells were removed by repeated 
washing and the remaining adherent fraction was cultured over 7 days at 37°C and 
5% CO2 in the presence of 10% FBS. The medium was not replaced throughout the 
culture period and no further exogenous agent was added in order to allow 
spontaneous monocyte differentiation into resting macrophages (M0).  
3.2.2 Percoll gradient and CSF-1 driven differentiation 
After the Ficoll separation PBMCs could be separated with a Percoll density 
gradient, to obtain pure monocytes. The separation of monocytes from 
lymphocytes was performed with a high-density hyper-osmotic Percoll density 
gradient: the PBMC suspension, containing 150-200x10
6
 cells, was layered above it 
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in a 1:3.33ml ratio. After being centrifuged at 600g for 15 min, the cells at the 
interface were collected and washed with serum-free RPMI, counted and seeded in 
RPMI +10% FBS in the presence of 20 nM CSF-1 (Repnik et all, 2003). Cells were 
cultured over 7 days at 37°C and 5% CO2, and the medium was changed every three 
days, adding fresh CSF-1. 
Cell morphology was monitored during both differentiation transitions from 
monocyte to macrophages as well as at the end of polarization protocols, and 
images were recorded using a phase contrast Nikon Eclipse Ti-S microscope (20x or 
40x magnification). 
 
3.3. PROTOCOLS OF POLARIZED ACTIVATION 
After removing the culture medium of differentiation, M0 macrophages were 
polarized toward M1 phenotype by incubation with LPS (0.1-1 µg/ml) for 24 or 48h. 
M2 polarization was obtained by adding IL-4 (20 ng/ml) and IL-13 (5 ng/ml) for 24 or 
48h. In selected experiments M0 cells were challenged overnight with either 100 
nM dexamethasone or 30-min pre-treatment with curcumin analogues before 
polarized activation (Table 3.1). As an internal positive control to confirm the 
possible effect of our curcumin-based analogues on the TLRs pathway we used 
CLI095 (Sigma). CLI-095, also known as TAK-242, is a novel cyclohexene derivative 
that suppresses specifically TLR4 signaling, inhibiting the production of NO and pro-
inflammatory cytokines (Li et al., 2006). It acts by blocking the signaling mediated by 
the intracellular domain of TLR4, but not the extracellular domain. It potently 
suppresses both ligand-dependent and -independent signaling of TLR4 (Kawamoto 
et al., 2008). 
After polarization, macrophages were harvested by gently scraping culture plates 
with 1ml PBS containing 5 mM EDTA and 2% FBS for qPCR and Western blot 
analysis. Additional cell samples were collected in a round bottom tube for flow 
cytometry for phenotype characterization and cytokine detection, and analyzed 
using a FacsCanto II flow cytometer (BD Biosciences Pharmigen San Diego, CA, US). 
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 Color of the solution Concentration 
Curcumin yellow 7.5 µM 
GG6 yellow 7.5 µM 
GG9 No color 7.5 µM 
CLI095 No color 1 µM 
Table 3.1: Curcumin analogues concentration and characteristics.  
To obtain Macrophage Conditioned Media (MCM) experiments were performed by 
polarizing the cells toward M1/M2 immunophenotypes for 48h as described above 
and incubating for further 72h in the absence of any activating agent. At the end of 
this period MCM was harvested and concentrated 10x using Amicon Ultra-15 
centrifugal filter units with Ultracel-PL, cut-off 3 KDa (Millipore/Merk, Darmstadt, 
Germany). The MCM was stored at -20°C until further analysis using the Luminex 
Technology (Luminex Corporation, Austin, TX, US). 
 
3.4. FLOW CYTOMETRY 
3.4.1 Evaluation of leukocyte populations in a whole blood sample 
We first analyzed the different leukocyte populations (lymphocytes, monocytes, 
granulocytes) in a sample of whole blood collected from the buffy coat used for 
monocyte separation. Blood was diluted 1:2 with saline buffer (0.9% NaCl) and then 
incubated with 2 ml of lysis buffer 1 (0.2% NaCl w/v) for 10 min at room 
temperature to lyse the erythrocytes, followed immediately by the addition of lysis 
buffer 1 (1.6% NaCl, 0.2% sucrose) for a further 10-min incubation. The sample was 
centrifuged at 300g for 5 min at room temperature, and the white cell pellet was 
washed twice in PBS/EDTA, suspended in 500 μl of PBS containing 2% FBS and 
analyzed by flow cytometry (Beckman Coulter Epics XL). A two-dimensional dot plot 
hystogram displayed a light scatter plot of white blood cells passing through a flow 
cytometer. The X-axis shows forward light scatter (FS) indicative of cell size, 
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whereas the y-axis shows side light scatter (SS) indicative of cell granularity. The 
correct voltage settings of these two parameters permitted to discriminate the free 
PBMCs populations. 
3.4.2 Identification and characterization of monocyte subsets 
Identification of monocyte subsets was performed using multiparameter flow 
cytometry. For analysis of classical and non-classical monocytes, cells were stained 
with a FITC or phycoerythrin (PE) anti-CD14 monoclonal antibody (mAb). The 
analysis was performed according to standardized gating strategy (Ziegler-Heitbrock 
et al., 2010). The relative frequency of these monocyte subsets were expressed as 
the percentage of the total monocyte gate. 
3.4.3 Characterization of human macrophage phenotypes by flow cytometry 
Human macrophages were harvested by gently scraping culture plates with PBS 
containing 5 mM EDTA, collected in round-bottom tubes for immunolabeling (BD 
Biosciences) and resuspended at 10
6
/ml in 100 µl PBS with 2% FBS to block Fc 
receptors. Purity in these cultures was first assessed by staining cells with PE-anti-
CD14 (20 μl/106 cells), which is a well-known circulating monocyte marker, also 
expressed on mature macrophage surface; furthermore, we excluded lymphocyte 
contamination by staining cells with PeCy7-labeled antibody against CD3 (5μl/106 
cells), an antigen bound to the membranes of all mature T-cells. 
In order to characterize the phenotypes of spontaneously human monocyte-derived 
macrophages, we analyzed specific surface marker expression of resting, M1 and 
M2 polarized immunophenotypes. Macrophages were stained for 30 min in the 
dark with fluorochrome-tagged monoclonal antibodies against surface CD80-FITC 
(20μl/106 cells) and CCR2-APC (10μl/105 cells) to typify the M1 phenotype, and 
against CD206-FITC (20μl/106 cells) and CD163-PE (20μl/106 cells) to characterize 
the M2 phenotype. The last panel of M1/M2 markers was selected based on a 
characterization performed in human monocytes (Fadini et al, 2013). After 
incubation with specific antibodies, samples were washed and suspended in 250 μl 
PBS/EDTA, and 10,000 events/sample for each tube were recorded in a FacsCanto II 
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flow cytometer (BD Biosciences). Data were analyzed using the FacsDiva software 
(BD Biosciences). Isotype-matched controls were used as a reference. 
Expression of each surface antigen and its modulation after stimulus was evaluated 
individually or in combination with other markers, in order to explore how 
polarization can affect macrophage phenotypes by down-regulating or enhancing 
surface protein expression or localization within the cells. During analysis, typically 
less than 2% positive cells were allowed beyond the statistical marker in 
appropriate controls.  
3.4.4 Intracellular cytokine production 
Intracellular cytokine production was evaluated using flow cytometry in monocyte-
derived macrophages. After spontaneous differentiation, macrophages were 
stimulated with either LPS (1 µg/ml) or IL-4 (20 ng/ml) plus IL-13 (5 ng/ml) for 6 h. 
Cells were pretreated with brefeldin (10 µM) to block cytokine secretion. At the end 
of stimulus, cells were harvested by gently scraping culture plates with 1 ml PBS 
containing 5 mM EDTA and 2% FBS. Cells were collected in a round bottom tube for 
flow cytometry and processed for immunostaining. 
Where indicated, whole blood samples or monocyte-derived macrophages were 
treated with 100 nM dexamethasone overnight or with curcumin analogues 30 min 
before stimulation. 
Macrophage pellets were fixed with 100 μl 4% paraformaldehyde solution and 
permeabilized by adding 2 ml of Perm Buffer solution containing 0.1% saponin and 
0.009% sodium azide. Cells were centrifuged twice and incubated in 100 μl Perm 
Buffer solution in the presence of FITC-anti-IL-1β (5 μl/106 cells) for 20 min in the 
dark. Subsequently, cells were washed, resuspended in 250 μl PBS/EDTA, and 
10,000-50,000 events/sample for each tube were recorded. 
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3.5. GENE EXPRESSION ANALYSIS 
Total RNA was isolated from about 6x10
5
 cells. Cells were washed once in PBS and 
RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Switzerland). cDNA was 
generated from 200 ng total RNA (nanodrop Thermo Scientific, Reinach, 
Switzerland) using RevertAid Reverse Transcriptase and random primers according 
to the ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. The ƌelatiǀe ƋuaŶtifiĐatioŶ of the geŶes of 
interest was measured by real-time quantitative PCR (Q-PCR) performed using Max 
SYBR Green PCR Master Mix for 40 cycles of denaturation (15 sec, 95°C), annealing 
(30 sec, 60°C) and extension (30 sec, 72°C) on a CFX96 Real-Time PCR Detection 
System thermocycler (Biorad, Milan, Italy). Oligonucleotide primers were designed 
using the online tool for Real-Time PCR Blast and obtained from Invitrogen. The 
primer sequences are shown in Table 3.2. Results were normalized using the 
housekeeping gene 18S, GAPDH and the ΔΔ cycle threshold method, and are 
expressed as relative fold of stimulated over control group, used as calibrator. 
 
 Forward Reverse 
18S AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA 
GAPDH CACCATCTTCCAGGAGCGAG CCTTCTCCATGGTGGTGAAGAC 
TNF-α TCCTTCAGACACCCTCAACC AGGCCCCAGTTTGAATTCTT 
IL-1β GGGCCTCAAGGAAAAGAATC TTCTGCTTGAGAGGTGCTGA 
IL-10 TGCAAAACCAAACCACAAGA TCTCGGAGATCTCGAAGCAT 
 
Table 3.2: qPCR primer sequences for the phenotypic characterization. The primers were 
designed using the online tool for Real-Time PCR Blast. 
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3.6. WESTERN BLOT 
For protein extraction, 6x10
5 
cells were seeded in 60-mm dishes. After polarized 
activation, cells were washed once with PBS and harvested in 150μl lysis buffer (50 
mM Tris HCl pH 7.4, 150 mM NaCl, 1% NP-40, 25mM NaF, 0.5% Na desoxycholate, 
10% SDS, 1mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 
1 mM phenyl-methyl-sulfonyl-fluoride (PMSF) and Complete® protease inhibitors 
(Roche). Each sample comprised two pooled plates and was stored at -20°C until 
further analysis. Protein concentration was determined by protein assay using 
Lowry protocol and reagents (Lowry et al., 1951). Protein lysates were heated at 
100°C for 5 min to denature proteins and 40 µg of each sample were loaded onto a 
10% SDS/polyacrylamide gel and run at 120V for 1h. Cell proteins were then 
transferred to PVDF membrane at 100V for 1h at room temperature, using a 25mM 
Tris, 192nM glycine and 20% methanol buffer. The membrane was blocked with 5% 
milk in TBS (1M Tris HCl pH 7.4, 5M NaCl, 0.1% Tween 20) for 1h at room 
temperature, washed, and then incubated with specific primary antibodies against 
IκB-α and GADPH (Table 3.3). Immunolabeled proteins were detected by using 
appropriate HRP-conjugated secondary antibodies, and immunoreactive bands 
were revealed using enhanced chemiluminescence (ECL) detection. Band intensities 
were normalized to GADPH. The intensity of each blot was measured using the 
ImageJ software. 
 
Protein primary antibody Secondary antibody 
 Origin Dilution  Dilution 
IκB-α Rabbit monoclonal 1:1000 Anti- rabbit 1:5000 
GAPDH Rabbit monoclonal 1:1000 Anti- rabbit 1:5000 
 
Table 3.3: Antibodies used for Western blot analysis 
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3.7. ELISA ASSAY 
Monocytes were plated in 24-well plates at a density of 10
6
 cells per well, 
respectively, using culture medium and allowed to differentiate for 7 days. Cells 
were primed by pre-treating with 1 μg/ml LPS or other TLR ligands as indicated in 
the presence or absence of curcumin analogues (optimal concentration of TLR 
activator chosen from preliminary experiments) for 6 h in culture medium (Ferrari 
et al, 1997). The TLR ligands used did not affect cell viability. It should be pointed 
out that commercial sources of LPS are frequently contaminated by other bacterial 
components, such as lipoproteins, capable of activating both TLR2 and TLR4. The 
Ultra-Pure LPS-EB preparation used here only activates TLR4 (InvivoGen). Cell 
supeƌŶataŶts ǁeƌe ĐolleĐted aŶd stoƌed at −ϮϬ°C uŶtil the daǇ of assaǇ ;aǀoidiŶg 
repeated freeze-thaw cycles). Cell lysates were prepared by adding to each 24-well 
culture 40 μl of lysis solution. The IL-1β content of culture medium and cell lysates 
was analyzed using commercially available enzyme-linked immunosorbent assay 
(ELISA) kits according to the manufacturer's instructions (Antigenix America, 
Huntington Station, NY, USA). The IL-1β ELISA assay kit does not distinguish 
between the inactive 31-kDa precursor (pro-IL-1β) and the bioactive 17-kDa mature 
form (as is the case for all commercially available kits). Standards with known 
amounts of IL-1β were used to convert values into absolute concentrations of IL-1β 
in pg/ml. 
 
3.8. STATISTICAL ANALYSIS 
Statistical analysis was performed using Prism software (GraphPad Software Inc, La 
Jolla, CA, US). Data were expressed as mean ± SEM. ANOVA followed by Bonferroni 
post-hoc test were used for comparison between samples. A P value < 0.05 was 
considered to be statistically significant. 
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4. Results 
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4.1. HUMAN MONOCYTE-DERIVED MACROPHAGE CULTURES 
4.1.1 Leukocyte distribution in human peripheral blood samples 
We initially evaluated leukocyte populations in human blood samples by flow 
cytometry. Fig. 4.1 shows a two-dimensional dot plot histogram displaying a light 
scatter plot of white blood cells obtained from buffy coats after erythrocyte lysis 
passing through a flow cytometer. In particular, the x-axis shows forward light 
scatter (FS) indicative of cell size, whereas the y-axis shows side light scatter (SS), 
indicative of cell granularity. The correct voltage settings of these two parameters 
allow large and very granular cells (granulocytes) to be differentiated from the 
smaller, less granular cells (monocytes) and, furthermore, from the even smaller 
lymphocytes. In particular, in the representative plot shown below, monocytes 
represented about 10% of total leukocytes in human blood, as reported previously 
(Auffray et al., 2009). 
 
 
Figure 4.1: The three main components of human leukocytes (lymphocytes, monocytes and 
granulocytes) are represented on the dot plot following flow cytometry. The three distinct 
populations can be distinguished based on their size and cell complexity (granularity). 
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4.1.2 Characterization of human monocyte-derived macrophages 
Blood samples from buffy coats were stratified on a Ficoll-Paque solution and the 
lympho-monocyte fraction was separated by density gradient centrifugation. The 
PBMC ring was then stratified upon a hyperosmotic Percoll solution to obtain pure 
monocytes that were cultured in the presence of CSF-1 (Fig. 4.2, right panels). After 
plating, morphology and size of adherent monocytes were observed over the 
differentiation period. Cell growth and differentiation were monitored from day 1 
to 6. We observed that at day 1 monocytes were small and round. As expected, at 
day 3 of culture they showed a larger cytoplasm volume than that of monocytes, 
possibly due to increased cytosolic organelle size (Fig. 4.2), which further increased 
till day 6. A largely comparable differentiation profile characterized FBS-driven 
macrophages culture (Tedesco et al., 2015). 
 
 
Figure 4.2: Morphological changes of monocytes during differentiation into macrophages. 20x 
magnifications, Nikon Eclipse Ti microscope. 
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In order to determine the extent of lymphocyte contamination, both cultures were 
stained with antibodies against CD14 (for monocytes-macrophages) and CD3 (for 
lymphocytes) surface markers. In FBS-driven macrophages at day 1, about 30% of 
adherent cells were found to be CD3
+
, while during the differentiation period the 
lymphocyte fraction declined progressively until day 8, when only about 15% of 
cells were CD3
+
. In contrast, in the CSF-1-driven macrophage population at day 1 
about 3% of adherent cells were CD3
+
 but this percentage fell to 0% at day 8. A 
representative experiment in Fig. 4.3 for FBS-driven macrophages at the end of the 
differentiation period showed 76.4% of CD14
+
cells (blue events) and 17.4% of CD3
+
 
cells (green events), respectively, while CSF-1-driven macrophages showed 89.2% of 
CD14
+
cells (blue events) and 0% of CD3
+
 cells (green events), respectively. Thus, at 
the end of the differentiation period, a minor fraction of CD3
+
 cells was detectable 
in our FBS-macrophage culture consistent with previous studies using a similar 
differentiation protocol (Eligini et al., 2013), but a pure culture (0% CD3
+
) was 
obtained using the CSF-1 protocol. 
 
Figure 4.3: Representative flow cytometry dot plots of surface CD3 and CD14 expression in a 7-day 
culture of monocyte-derived macrophages. Cells were stained with PeCy7-anti CD3 antibody for the 
lymphocyte population (green events) and PE-anti CD14 antibody for the macrophage population 
(blue events). The back-gating strategy allowed localizing these populations within the FS/SS plot 
(lower left panel). 
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We then characterized the resting macrophage phenotypes by flow cytometry at 
day 8 of differentiation (Fig. 4.4). A fraction of the cells from both protocols stained 
positively for the surface M1 markers CD80 and CCR2 and for the M2 markers 
CD206 and CD163. FBS- (Fig. 4.4A) and CSF-1-driven (Fig. 4.4B) resting macrophages 
displayed a predominant M2 vs. M1 phenotype, as defined by positive staining for 
CDϭϲϯ aŶd CDϮϬϲ. IŶ ďoth pƌotoĐols these peƌĐeŶtages ƌefleĐted ͞ŵiǆed aĐtiǀated͟ 
cells expressing varying levels of the different M1 or M2 markers, but with a major 
subpopulation that was more M2-oriented than M1-oriented.  
 
 
 
Figure 4.4: Phenotypic markers of resting human monocyte-derived macrophages at day 8 of 
differentiation. Bar graph of FBS- (panel A) and CSF-1- (panel B) driven macrophages show the 
percentage of M1 (CD80
+
/CCR2
+
) and M2 cells (CD206
+
/CD163
+
)as mean (± SEM) of 4 independent 
experiments. 
 
 
4.2. IMMUNOPHENOTYPING OF CSF-1 DIFFERENTIATED MACROPHAGES  
Immunophenotypes of CSF-1-driven human monocyte-derived macrophage were 
further characterized by analyzing specific surface markers expression in cells 
cultured in the growth medium supplemented with CSF-1 (M0) or in the presence of 
a pro- (LPS) or anti-inflammatory (IL-4/IL-13) microenvironment. 
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4.2.1 Characterization of macrophage morphotypes 
At the end of differentiation, resting macrophages (M0) showed two dominant and 
distinct morphotypes as observed by phase contrast microscopy (Fig. 4.5): 
spindle/elongated and round-͞fƌied-egg͟ shaped, ǁhiĐh ƌoutiŶelǇ oĐĐuƌƌed iŶ 
resting cultures consistent with recent studies (Eligini et al., 2013; Ambarus et al., 
2012a). Following 24h activation with either LPS to induce the M1 phenotype or 
with IL-4/IL-13 to obtain the M2 phenotype, cell morphology changed: in fact, M1-
polarized macrophages were enriched in the long and spindle-shaped morphotype 
(Fig. 4.5B), while M2 polarized macrophages were largely round-shaped (Fig. 4.5C). 
These observations suggest that polarized activation affected macrophage 
morphology. 
 
Figure 4.5: Phase contrast images of macrophages differentiated from monocytes, in resting state 
(M0, A) and after activation with LPS (M1, B) or IL-4/IL-13 (M2, C) for 24h. Circles indicate the CSF-1-
differentiated macrophage heterogeneous population (A) and enrichment for the two main spindle-
shaped (B) or round (C) morphotypes. Representative images were captured from macrophages 
obtained from the same donor. 20x magnification, Nikon Eclipse Ti microscope. 
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4.2.2 Characterization of the M1 macrophage subset 
We then analyzed the fraction of M1 macrophages by flow cytometry as defined by 
either positive single-staining for CD80 and CCR2 or by specific double-staining of 
CD80
+
/CCR2
+
 cells. Graphs in Fig. 4.6 show that, under resting conditions, 7.7±5.0% 
of M0 macrophages were CD80
+
(panel B) and 1.1±0.57% were CD80
+
/CCR2
+
 (panel 
D; see also the representative flow cytometry analysis in Fig. 4.6A). Following 
incubation with LPS for 24h, the amount of CD80
+
 macrophages increased (35.8±8.6 
vs. 7.7±5.0%, p<0.02; n=4, Fig. 4.6B; see also Fig. 4.6A) and a tendency was 
observed for CCR2
+
 cells as well (24.3±12.9 vs. 4.8±1.7%; n=4, Fig 4.6C). A significant 
modulation of CD80
+
/CCR2
+ 
cells was observed, compared with resting 
macrophages (4.6±1.07 vs. 1.1±0.57%; p<0.02; n=4, Fig. 4.6D; see also Fig. 4.6A red 
box). M2 polarized activation with IL-4/IL-13 did not significantly affect the fraction 
of CD80
+
 and CD80
+
/CCR2
+
 cells compared with resting macrophages (4.2±1.3 vs. 
7.7±5.0% for CD80
+ 
cells and 1.1±0.3 vs 1.1±0.6% for CD80
+
/CCR2
+ 
cells, 
respectively; panel B and D, n=4). 
 
Figure 4.6: Staining of M1 macrophages as defined by CD80
+
 and CCR2
+
 cells. Cells were 
differentiated from monocytes in RPMI 1640 + 10% FBS + CSF-1 for 7 days and thereafter activated 
with LPS or IL-4/IL-13 for 24h. Fluorescence quantification dot plots (A) are from a representative 
experiment: red boxes highlight CD80
+
/CCR2
+
cells and their modulation after M1 and M2 
polarization. Bars represent the mean (±SEM) of CD80
+
 (panel B), CCR2
+
 (panel C) and CD80
+
/CCR2
+ 
(panel D) cells from 4 independent experiments. *p<0.02 vs resting. 
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4.2.3 Characterization of the M2/anti-inflammatory macrophage subset 
We next analyzed the M2/anti-inflammatory subset by flow cytometry as defined 
by CD163
+
, CD206
+
 or specific double CD206
+
/CD163
+ 
staining. In resting state, 
63.1±3.7% of cultured macrophages were CD206
+
, and 5.8±1.7% were CD163
+
. After 
polarization with LPS, the percentages of CD206
+
 as well as CD163
+
 cells significantly 
decreased compared with resting macrophages (43.1±4.1 vs 63.1±3.7% CD206
+
, Fig. 
4.7B; 1.6±0.8 vs. 5.8±1.7% CD163
+
, p<0.05, n=3, Fig. 4.7C). Similarly, LPS treatment 
decreased the abundance of the double-stained CD206
+
/CD163
+
 cell subpopulation 
with respect to resting macrophages (0.9±0.4 vs 5±1.3% CD206
+
/CD163
+
, p<0.05, 
n=3, Fig. 4.7D; see also Fig. 4.7A, green box). Following activation with IL-4/IL-13 for 
24h, the percentage of cells specifically stained for each marker did not differ from 
that in resting cells (Fig. 4.7B and C). Similar results were obtained for the 
CD206
+
/CD163
+
 subpopulation (Fig. 4.7D). 
 
Figure 4.7: Quantification of M2 macrophage markers as percentage of CD206
+
, CD163
+
cells. CSF-1 
differentiated macrophages were polarized as described in the legend to Fig. 4.6 above and stained 
with FITC-anti-CD206 and PE-anti-CD163 specific antibodies. Fluorescence quantification dot plots 
(A) are from a representative experiment: green boxes highlight CD206
+
/CD163
+
 cells. Bars represent 
the mean (±SEM) of CD206
+ 
(panel B), CD163
+
 (panel C) and CD206
+
/CD163
+
 (panel D) cells of 3 
independent experiments. *p<0.05 vs resting. 
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We then performed a set of experiments with the human monocyte cells line THP-1 
to further validate our methods and markers in a condition of total absence of CD3
+
 
cells. THP-1 derives from human acute monocytic leukemia and can be 
differentiated to macrophages by adding phorbol ester (TPA, 185nM) for 6h in vitro 
(Tjiu et al., 2009). We monitored the differentiation and activation (100 ng/ml LPS 
and 20 ng/ml IFNγ for M1; IL-4 20 ng/ml and IL-13 20ng/ml for M2 phenotypes, 
respectively) through contrast-phase microscopy (Fig. 4.8 panels A-C) and flow 
cytometry (Fig. 4.8 panels D-F). Like CSF-derived macrophages, THP-1 shown two 
main distinct morphotypes of elongated and round cells, routinely occurring in 
resting cultures (Fig. 4.8A). Morphology was further affected by subsequent 
polaƌizatioŶ iŶ that LP“/IFNγ-activated macrophages were enriched in the long and 
spindle-shaped morphotype (Fig. 4.8B), while IL-4/IL-13 activated THP-1 
macrophages were largely round-shaped (Fig. 4.8C).  
 
Figure 4.8: Contrast images of THP-1-derived macrophages. THP-1 monocytes were differentiated in 
vitro to macrophages in RPMI 1640 + 10% FBS in the presence of 185nM TPA for 6h. At this time 
monocytes were considered to be differentiated into resting macrophages (A), and thereafter 
activated with LPS/ IFNγ(B) or IL-4/IL-13(C) for 24 h. The cell population comprised two main round 
and spindle-shaped morphotypes. Representative images are shown, 20× magnification. THP-1 
activated macrophages were stained with FITC-anti-CD14, PE-anti-CD86, PECy5-anti-CD80, APC-anti-
CD206 and PECy5.5-anti-CD163 specific antibodies. Graphs represent the mean (±SEM) of CD14
+ 
(panel D), CD80
+
/CD86
+
 (panel E) and CD206
+
 (panel F) cells of 3 independent experiments. 
 
50 
 
We then performed a time course by flow cytometry investigating the changes in 
CD14, CD80/CD86 (M1) and CD206/CD163 (M2) expression (Fig. 4.8 panels D-F). Fig. 
8D shows that the percentage of CD14
+
 cells was high (around 96%) after 6 h TPA 
and remained high also after 24h of M1- (red dots) or M2- (green dots) activation. 
Only after 48-h activation the level started to decrease in all samples (resting: from 
92.1±0.6 at 24h to 76.8±5.7% at 48h; M1: from 96.5±0.3 at 24h to 82.1±7.8% at 
48h; M2: from 79.1±4.6 at 24h to 46.1±10% at 48h). The double positive 
CD80
+
/CD86
+
 subpopulation used to describe the M1 phenotype increased after 
24h, but more after 48-h LP“/IFNγ-activation (Fig. 4.8E). The CD80+/CD86+ cells 
were not affected in resting and M2 THP-1 cells, and remained low. THP-1 
macrophages did not express detectable CD163 levels. The fraction of CD206
+
 cells 
was low and did not increase after IL-4/IL-13 activation (Fig.4. 8F). 
 
4.2.4 Analysis of macrophage conditioned medium 
The composition of macrophage conditioned medium (MCM) was characterized by 
Luminex x-MAP technology plates used for all multiplex cytokine kits. A total of 50 
predetermined analytes were analyzed and assays were run in triplicate according 
to the ŵaŶufaĐtuƌeƌs͛ pƌotoĐol. The fold-change for each individual cytokine for 
each of the multiplex kits is summarized in Fig. 4.9. As expected, M1 MCM showed 
the presence of high levels of pro-inflammatory cytokines and molecules like TNF-α, 
IL-ϭβ, IL-6 and VEGF compared to resting MCM, while M2 MCM displayed high 
levels of IL-4 and CCL22 cytokines (bar graphs in the left part of Fig. 4.9, n=3). The 
anti-inflammatory cytokine IL-10 was unexpectedly more abundant in M1 than in 
M2 MCM, with a 3-fold increase vs. resting MCM; in M2 and resting MCM, the level 
of IL-10 were comparable. The right panel in Fig. 4.9 depicts all cytokines detected 
and their fold-change compared to resting MCM (all n=3). 
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Figure 4.9: MCM composition of activated CSF-1 derived macrophages. Cells were polarized for 48h 
as described in the legend of Fig. 6 above and after activation FBS-free RPMI was added for 72h. 
Then the medium was collected, concentrated 10x and analyzed by Luminex x-MAP technology. 50 
analytes were evaluated including cytokines, growth factors, cell adhesion molecules, 
immunoglobulin and components of immune system. The graphs and table summarize the fold-
change for each individual cytokine of the multiplex kits. Data are shown as mean of 3 independent 
experiments run in triplicate. 
 
 
4.2.5 Gene expression profile of target cytokines 
We further characterized the immunophenotypes obtained after either M1 or M2 
polarization by performing qRT-PCR analysis for TNF-α, IL-ϭβ aŶd IL-10 mRNA levels. 
In another set of experiments (see section 4.2.4 above) we analyzed the same 
cytokines released in the media by Luminex technology. After 6 h stimulation with 
LPS, macrophages showed higher mRNA levels of the genes encoding for TNF-α 
(3195±598 fold change, p<0.05, Fig. 4.10B) and IL-ϭβ ;ϱϭϲ±ϲϰ fold ĐhaŶge, p<Ϭ.Ϭϱ, 
Fig. 4.10A) compared with resting. The relative increase in mRNA levels after 48 h 
was more marked for IL-1β ;ϰϬϱϮ±879 fold change, p<0.005) than that for TNF-α 
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(399±167 fold change, p<0.05). Conversely, mRNA levels for TNF-α ƌose ŵoƌe 
sharply after 6h and decreased after 48h (3195±598 fold change at 6h vs. 399±167 
fold change at 48h, Fig. 4.10B). Macrophages stimulated for 6 and 48h with IL-4/IL-
13 to enhance the M2 phenotype displayed comparable mRNA levels of genes 
encoding both IL-ϭβ aŶd TNF-α ǁith ƌespeĐt to those of ƌestiŶg ŵaĐƌophages ;Fig. 
4.10, panels A and B respectively). The mRNA encoding the anti-inflammatory 
cytokine IL-10 was unexpectedly more abundant in LPS-treated (M1) cells than in 
those treated with IL-4/IL-13 (M2) at both time points (792±10 (M1) vs 2.5±0.6 (M2) 
fold change at 6 h, p<0.005; 11.3±3.5 (M1) vs. 3.6±2.5 (M2) fold change at 48 h; 
p<0.05, Fig. 4.10C). In particular, IL-10 mRNA peaked after 6h incubation with LPS 
(Fig. 4.10C). 
 
 
 
Figure 4.10: mRNA expression profiles of M1 and M2 phenotypic markers. Macrophages were 
differentiated from monocytes for 7 days in RPMI1640 + 10% FBS +CSF-1 and thereafter incubated 
with fresh medium (Resting, gray lines) or activated with LPS (M1, red lines) or IL-4/IL-13 (M2, green 
lines) for 6 or 48h. IL-ϭβ ;paŶel AͿ, TNF-α ;paŶel BͿ aŶd IL-10 (panel C) mRNA levels were measured 
by Q-PCR and normalized to GAPDH. The mRNA level of selected genes in resting macrophages was 
assigned a value of 1, and mRNA levels following activation were shown relative to resting. Data are 
shown as mean (±SEM) of 3 independent experiments. *p<0.05 and **p<0.005 vs. resting. 
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4.3. PHENOTYPIC MODULATION BY CURCUMIN ANALOGUES 
4.3.1 Specific staining of curcumin and curcumin analogues 
To investigate the effect of curcumin on macrophage activation we performed flow 
cytometry experiments with curcumin and its analogues. One unexpected finding 
was that curcumin and GG6, but not GG9, interfered with the flow cytometer laser 
detection, showing high levels of positive cells for all fluorophores on the green 
laser (532-562 nM) as shown in the representative plots of Fig. 4.11 (after 24-h 
treatment: 4.6% CD80
+
 cells in resting, 66.0% curcumin, 5.5% GG9 and 63.1% LPS 
groups, respectively). Because curcumin and GG6 yield yellow solutions, this 
pigment is able to interfere with the flow analysis. Based on these findings we 
decided to exclude these two compounds from further flow cytometry analysis. 
 
Figure 4.11: Percentage of CD80
+
 cells after macrophage differentiation. The percentages described 
CD80
+
 Đells afteƌ Ϯϰh of stiŵulatioŶ ǁith ĐuƌĐuŵiŶ ;ϳ.ϱμMͿ, GGϵ ;ϳ.ϱμMͿ oƌ LP“ ;ϭϬϬŶg/ŵLͿ. 
Fluorescence quantification dot plots from a single experiment. 
 
 
4.3.2 Effects of dexamethasone and curcumin analogues on macrophage 
activation 
We then evaluated the effect of dexamethasone (Dexa) and curcumin analogues on 
macrophage immunophenotypes after activation. Cells were pre-treated with dexa 
(100 nM), CLI095 (1 μMͿ or curcumin analogues (7.5 μMͿ for 30 min, and 
subsequently incubated with fresh medium to obtain resting macrophages (M0) or 
in the presence of either LPS or IL-4/IL-13 to obtain macrophages activated to M1 
and M2 phenotypes, respectively.  
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First we investigated the effects of these compounds on M1 markers, expressed as 
CD80
+
, CCR2
+
 and CD80
+
/CCR2
+
 cells. As shown in Fig. 4.12B, the curcumin analogue 
GG9, as well as dexamethasone and CLI095, were able to significantly decreased the 
LPS-induced up-regulation of CD80
+
 cells (LPS 42±6.2% vs. resting 10.1±3.5%, 
p<0.005, n=6, Fig. 4.12B) after 24h (dexa 11.2±3.6% vs. 42±6.2%, GG9 22.9±4.8 vs. 
42±6.2%, CLI095 13.5±4 vs. 42±6.2%, p< 0.05, n= 6; Fig. 4.12B; see also Fig. 4.12A). 
No significant effects of curcumin analogues were seen in CCR2
+
cells (Fig. 4.12C). 
 
 
Figure 4.12: Fraction of M1 macrophages as defined by CD80
+
and CCR2
+
 cells. Cells were pre-treated 
with dexa and curcumin analogues for 30 min and then polarized as described in the legend to Fig. 
4.6 above. Fluorescence quantification dot plots (A) are from a representative experiment. Bars 
represent the mean (±SEM) of CD80
+
 (panel B) and CCR2
+
 (panel C) cells from 6 independent 
experiments. *p<0.01 vs resting, °p<0.05 vs LPS. 
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No significant effects of curcumin analogues were observed on the double positive 
CD80
+
/CCR2
+
 cells (Fig. 4.13). Only pre-treatment with dexa was able to significantly 
prevent the up-regulation of CD80
+
/CCR2
+
 cells induced by LPS (0.7±0.3% vs 
3±1.2%, °p<0.05, n=6, Fig.4.13). 
 
Figure 4.13: Percentage of M1 macrophages as defined by CD80
+
/CCR2
+
 cells. Cells were treated as 
described in the legend to Fig. 4.12 above. Bars represent the mean (±SEM) of CD80
+
/CCR2
+
cells 
from 6 independent experiments. °p<0.05 vs LPS. 
 
 
To further characterize the effect of curcumin analogues on macrophage activation 
we investigated the modulation of M2 markers CD163 and CD206 after activation. 
Fig. 4.14A shows that, under basal conditions, glucocorticoid treatment significantly 
increased the percentages of CD206
+
/CD163
+
 subpopulations with respect to 
untreated macrophages (8.8±2.2 vs 3.4±0.9%, *p<0.05, n=3), as previously 
published by our group (Tedesco et al., 2015). Pre-treatment with GG9 did not 
affect the percentages of CD206
+
/CD163
+
 cells after 24h (Fig. 4.14A). Fig. 14B shows 
that dexa treatment prevented the decrease in M2 macrophages, as measured 
taking into account the fraction of CD206
+
/CD163
+
 cells, induced by pro-
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inflammatory activation (5.9±2.0 vs 1.1±0.4%, n=5). Treatment with the curcumin 
analogue GG9 did the same through a significant effect in counteracting the LPS-
induced down-regulation of CD206
+
/CD163
+
cells (3.4±1.0 vs 1.1±0.4%, n=5, Fig. 
4.14B). CLI095 again had a similar and significant effect upon LPS activation (3.4±0.8 
vs 1.1±0.4%, °p<0.05, n=5). 
 
Figure 4.14: Percentage of M2 macrophages as defined by CD206
+
/CD163
+
 cells. Cells were treated 
as described in the legend to Fig. 4.12 above. Bars represent the mean (±SEM) of 
CD206
+
/CD163
+
cells in basal condition (panel A) and CD206
+
/CD163
+
cells with curcumin analogues 
pre-treatment and LPS activation (panel B) from 3-5 independent experiments. *p<0.05 and 
**p<0.005 vs resting, °p<0.05 vs LPS. 
 
4.3.3 Effect of curcumin analogues upon NF-κB activation 
We then assessed whether curcumin analogues modulated IκB-α expression 
profiles, as an index of NF-κB aĐtiǀatioŶ. After 30 min incubation with LPS (M1), IκB-
α expression was significantly down-regulated by 40% compared with resting 
macrophages (Fig. 4.15). In particular, 30 min pre-treatment with GG9 did not alter 
the protein level with respect to LPS, as shown in Fig. 15, whereas curcumin, GG6 
and CLI095 significantly reverted NF-κB aĐtiǀatioŶ ;GGϲ Ϭ.ϵϰ±Ϭ.ϭϮ, ĐuƌĐuŵiŶ 
0.83±0.08, CLI095 1.0±0.09 vs. LPS 0.6±0.04, p<0.05, n=3; Fig. 4.15). 
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Figure 4.15: IκB-α expression in CSF-1-driven macrophages. Total protein extracts from resting, 
untreated M1 and curcumin analogue-pretreated macrophages showed a significant down-
regulation of IκB-α after 30 min LPS incubation. GADPH served as loading control. Bars represent the 
mean (±SEM) of 3 independent experiments. Results from a representative immunoblot are shown. 
**p<0.0005 vs resting, °p<0.05 vs LPS. 
 
 
4.3.4 Effects of curcumin analogues and CLIO95 on IL-1β production in cultured 
macrophages 
We measured the percentage of CSF-1-derived macrophages expressing 
intracellular IL-ϭβ aŶd iŶǀestigated ǁhetheƌ GGϵ oƌ CLIϬϵϱ pƌe-treatment could 
influence this process. As shown in Fig. 4.16B, a small fraction of IL-ϭβ+ cells 
(1.4±0.1%) was detected under basal conditions. Following 24-h incubation with 
LPS, the fraction of cells staining for cell-bound IL-ϭβ ǁas sigŶifiĐaŶtlǇ iŶĐƌeased 
(19.8±5 vs 1.4±0.1% IL-ϭβ+ cells vs. unstimulated, p<0.01, n=4, Fig.4. 16B). 
Compared with M1 cells, 30 min pre-treatment with either GG9 or CLI095 
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significantly decreased the percentage of IL-ϭβ+cells (6.1±2.6% GG9, 1.6±0.4% 
CLI095 vs 20.7±7 % LPS, p<0.05, n=4, Fig. 4.16B). 
 
Figure 4.16: Effect of GG9 and CLI095 on CSF-1 derived macrophage cytokine expression. After 
differentiation, macrophages were pre-treated with GG9 or CLI095 for 30 min, and then incubated 
with LPS for 24h at 37°C in the presence of brefeldin (10 µM) to block cytokine secretion. Prior to 
flow cytometry analysis fixed/permeabilized cells were stained with a FITC-anti IL-ϭβ aŶtiďodǇ. Baƌ 
graph (B) represents the mean (±SEM) of 4 independent experiments, and fluorescence 
quantification dot plots (A) are from a representative experiment. *p<0.01 vs resting, °p<0.05 vs LPS. 
 
 
To further explore the effects of curcumin and its analogues on macrophage cell 
activation, the pro-inflammatory cytokine IL-ϭβ ǁas ƋuaŶtified ďoth iŶ the pƌoteiŶ 
lysate and in the medium. All these experiments were performed in FBS-free RPMI. 
Although the baseline level was very low, 24h of LPS stimulation significantly 
increased the production of intracellular IL-ϭβ (5302±1342 vs 160±84 pg/ml, p<0.01, 
n=3; Fig.4.17A). Curcumin and GG6 did not affect the levels of intracellular cytokine 
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but 30-min pre-treatment with GG9 and CLI095 significantly blocked LPS-induced IL-
ϭβ pƌoduĐtioŶ ;ϵϭϴ±Ϯϱϳ pg/ŵl GGϵ aŶd ϯϱϲ±ϮϴϮ CLIϬϵϱ vs 160±84 pg/ml, p<0.05, 
n=3; Fig. 4.17A). In untreated samples the basal level of IL-ϭβ ƌeleased iŶ the 
medium was not detectable (ND). In contrast, 24-h LPS activation induced a marked 
release of the pro-inflammatory cytokine by macrophages (740±210 pg/ml, p<0.05, 
n=2; Fig. 4.17B). Curcumin and GG6 did not affect the cytokine release whereas 30 
min GG9 pretreatment significantly inhibited it (101±101 vs 740±210 pg/ml, p<0.05, 
n=2; Fig. 4.17B). IL-ϭβ afteƌ CLIϬϵϱ pƌetƌeatŵeŶt aŶd LP“ stiŵulatioŶ ǁas Ŷot 
detectable (Fig. 4.17B).  
 
 
Figure 4.17: Assay of intracellular (panel A) and released (panel B) IL-ϭβ fƌoŵ C“F-1 derived 
macrophages. After differentiation, macrophages were pre-treated with curcumin, GG6, GG9 or 
CLI095 for 30 min, and then incubated with LPS for 24h at 37°C in FBS-free RPMI. After incubation, 
culture medium and cell lysate samples were harvested for IL-ϭβ aŶalǇsis ďǇ ELI“A. Baƌ gƌaph of 
panel A represents the mean (±SEM) of 3 independent experiments, and panel B represents the 
mean (±SEM) of 2 independent experiments. *p<0.05 vs resting, °p<0.05 vs LPS. 
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5. Discussion 
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The turmeric plant is an herb belonging to the ginger family and has been used 
throughout history as a dietary spice and coloring agent in Indian and Chinese 
cuisines. The rhizome part of the plant has also been used for centuries in Indian 
and Chinese traditional medicines but the first documented case of its use as a drug 
was only in 1937, when it was used to treat biliary disease (Akbik et al., 2014). The 
remarkable healing properties and safety of curcumin motivated research groups all 
over the world to study this natural product. Curcumin was shown to have many 
biological activities including antioxidant, cardio- and neuroprotective, antidiabetic, 
antimicrobial, antimalarial, anti-human immunodeficiency virus (HIV), 
thrombosuppressive, antitumour and chemopreventive actions in a variety of 
experimental settings (Oliveira et al., 2015). Due to a vast number of biological 
targets, curcumin has achieved the potential therapeutic interest to be included in 
treatment protocols of immune-related, metabolic diseases and cancer. Over the 
past few years, many review articles have been published on curcumin biological 
activities (Priyadarsini et al., 2003; Joe et al., 2004; Maheshwari et al., 2006; Menon 
and Sudherr, 2007; Ghosh et al., 2015). Several studies suggest that curcumin has a 
diverse range of molecular targets, supporting the view that this compound 
influences a variety of biochemical and molecular cascades. Most studies suggest 
that the biological effects of curcumin are mainly due to its ability to either bind 
directly to various proteins and regulatory enzymes or modulate the intracellular 
redox state (Priyadarsini et al., 2003; Menon and Sudherr, 2007). Modulation of 
cellular redox homeostasis exerts an indirect but more global effect on a number of 
cellular processes, since several critical transcription factors are sensitive to even 
minor fluctuations in the cell redox milieu. The intricate mechanism of action of 
curcumin involves various biological targets via transcription factors (i.e. NF-κB, NF-
AT, AP-1, signal transducers and activator of transcription (STAT) and p53) as well as 
kinases, cytokines release, and receptors found on different immune cell type. the 
above mechanisms control cell cycle, differentiation, stress response and other 
physiological processes. Although curcumin does not have a drug profile yet, the 
safety of oral curcumin (12 g/day), which is much higher than its regular intake as a 
food supplement, has been established by regulatory agencies (Lao et al., 2006). In 
response to the growing interest in curcumin and its biological activities, several 
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clinical trials have addressed the safety, pharmacokinetics and efficacy in humans. 
These trials have tested specific and promising biological activities of curcumin as 
shown by in vitro and preclinical assays (clinicaltrials.gov; Oliveira et al., 2015). 
However, there are certain limitations concerning the use of curcumin as a drug. 
Due to its insolubility in water, curcumin has very poor bioavailability, its cellular 
uptake is slow and it gets metabolized very fast once inside the cell. Therefore, it 
requires repeated oral doses in order to achieve significant intracellular 
concentrations for any physiological effects. To address these limitations, a large 
number of curcumin analogues with improved uptake, metabolism and activity 
have been designed (Srivastava et al., 2011). 
Curcumin appears to affect innate and adaptive immunity, especially in pathological 
conditions, by effectively modulating the function of T cells, B cells, DCs, monocytes, 
macrophages and neutrophils (Srivastava et al., 2011). Several reports have 
highlighted the anti-inflammatory action of curcumin and its potential role in the 
treatment of immune cell-related diseases. Few studies investigated the effect of 
curcumin and its analogues on macrophage activation. Mercanti et al. (2014) and 
Tocharus et al. (2012) studied the effects of curcumin on mouse microglia activation 
inhibiting the NO production induced by LPS and the IL-ϭβ, IL-6 and TNF-α ƌelease iŶ 
the medium. Another study demonstrated that curcumin induces macrophage M2 
polarization by increasing the production of IL-4 and/or IL-13 and STAT6-dependent 
manner (Gao et al., 2015), suggesting that curcumin and its anologues represent 
promising lead compounds targeting immune cells activation. Therefore, one 
specific aim of the present work was to test the potential of curcumin analogues as 
modulators of human macrophage function. 
Because recent advances in macrophage development and functional diversity 
indicate a multidimensional concept of macrophage ontogeny, activation and 
function (Ginhoux et al., 2015), research in pharmacological targeting of 
macrophage function is challenging. The diversity of terminology and inconsistent 
use of markers to describe macrophage activation impedes reaching a consensus in 
this research field. In fact, mononuclear phagocytes are an essential element in the 
orchestration and expression of innate immunity and adaptive immune responses. 
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It has been demonstrated that, in response to signals derived from microbes, 
damaged tissues or activated lymphocytes, monocyte/macrophages undergo a 
reprogramming which leads to the emergence of a spectrum of distinct functional 
phenotypes (Sica and Mantovani, 2012). According to the current framework, 
macrophages can be polarized into classically (M1) or alternatively (M2) activated 
cells, representing two polar extremes of signals computed by macrophages. The 
existence of at least two phenotypically and functionally distinct subsets of 
macrophages as well as circulating monocytes has been demonstrated in both 
humans and mice (Mosser and Edwards, 2008; Mantovani et al., 2009; Motwani 
and Gilroy, 2015). Because nature of polarizing agents and exposure time appear to 
be crucial, a panel of leading immunologists recently published experimental 
guidelines for macrophage activation and polarization (Murray et al., 2014). 
Thus, when we set out to explore the effect of curcumin on macrophage 
polarization, the first key step was to set up a model of human monocyte-derived 
macrophages. In the literature a variety of protocols are described to isolate blood 
circulating monocytes and promote monocyte-to-macrophage differentiation, each 
with its own pros and cons. In particular, macrophages can be obtained from 
immortalized cell lines (e.g., THP-1) or by purifying blood monocytes, either through 
magnetic cell sorting using specific CD14-labeled magnetic beads (Martinez et al., 
2013) or by density gradient centrifugation. Our published protocol involved: (i) 
monocyte isolation by Ficoll stratification, and (ii) spontaneous FBS-driven 
differentiation with no additional growth factors in the medium (Tedesco et al., 
2015). One limitation of this procedure, however, is that the FBS-driven 
macrophage population includes 20-30% of CD3
+
 cells 24 h after seeding that drop 
down to 10-15% at the end of differentiation. Our improved method as described 
herein is based on two gradient centrifugations upon polymers, first on Ficoll-paque 
and next on Percoll. Pure monocytes obtained using this method need to be 
cultured with CSF-1 in the medium to allow differentiation into macrophages. We 
then monitored and compared the differentiation period (from monocytes to 
macrophages in 7 days) and the purity of this CSF-1 driven culture. At 24 h from 
seeding, monocytes cultured by the CSF-1-driven protocol had no accompanying 
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CD3
+ 
cells. After 7 days FBS-driven CD3
+
percentage decreased and reached the 15% 
as reported by Eligini et al (2012), as noted above, but CSF-1-driven CD3
+
cells 
remained 0%. Therefore, our improved CSF-1-driven protocol generated diverse 
macrophage subpopulations with a virtually complete lack of CD3
+
 cells. During the 
ϳ daǇs͛ diffeƌeŶtiatioŶ ǁith ďoth pƌotoĐols ŵaĐƌophages iŶĐreased their size and 
acquired different shape and morphology, showing mainly two dominant and 
distinct morphotypes: spindle/elongated and round-/͞fƌied-egg͟ shaped, ǁhiĐh 
routinely occurred in resting cultures (Eligini et al., 2012; Vogel et al., 2014). The 
presence of two distinct macrophage subsets was confirmed by flow cytometry as a 
differential distribution on the forward scatter (FS) parameter, which is indicative of 
the cell size. In line with our results, Eligini and colleagues (2012) demonstrated the 
presence of two dominant monocyte-derived macrophages morphotypes under 
basal conditions. In particular, they highlighted the presence of about 50% spindle-
shaped cells that display an M1-like phenotype, and about 50% of round-shaped 
cells that display an M2-like phenotype utilizing laser capture microscopy followed 
by RT-PCR for characterization of specific immunophenotypes. Recently Vogel et al. 
(2014) confirmed these findings. At the end of differentiation resting macrophages 
(M0) from both protocols showed lower levels of CD80
+
/CCR2
+
 and higher fractions 
of CD206
+
/CD163
+
 cell subpopulations, indicating that in resting state macrophages 
pƌeseŶt a ŵaiŶ ͞MϮ-like͟ pheŶotǇpe. Hence the CSF-1 driven protocol allowed us to 
obtain a pure monocytes population and, after differentiation, a more 
homogeneous macrophage population.  
As opposed to other studies, we exposed macrophages to M1- and M2-activating 
agents only after these cells were fully differentiated and not during the 
differentiation period. On one hand, during inflammation monocytes will enter 
inflamed tissues and will be exposed to TLR-ligands or cytokines during their 
differentiation. However, tissue-resident macrophages, which have recently been 
shown to be self-renewed (Schulz et al, 2012; Okabe and Medzhitov, 2015), will in a 
lot of cases be exposed to these agents only after their differentiation. As a 
potential future research question, it would be very interesting to compare a similar 
cytokine exposure to monocytes and to differentiated macrophages, such as 3 days 
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of exposure during differentiation and then 3 days of exposure after differentiation. 
Along the same lines, it would be interesting to sort spontaneously differentiated 
M2 cells and then expose them to M1-triggers to see if they can switch from 
phenotype or not or if M2 cells that were exposed to IL-4/IL-13 during their 
differentiation could switch easily to M1 or are more locked in an M2 state. 
In the present work, we specifically polarized monocyte-derived macrophages with 
LPS to induce the M1 phenotype, or with IL-4/IL-13 to obtain the M2 phenotype 
(24-h incubation after differentiation period in both cases). We observed that 
macrophage polarized activation toward M1 or M2 immunophenotypes were 
accompanied by specific changes in cell morphology compared with resting state. In 
particular, we observed that M1 macrophages were enriched in the long, spindle-
shaped morphotype, while M2 macrophages were largely round-shaped. Similar 
observations were made by Eligini et al. (2012) and Vogel et al. (2014). As noted 
above, M1 and M2 phenotypes can be identified by a wide range of surface markers 
(CD cluster of differentiation, as well as cytokine and chemokine receptors) which 
are distinct between human and mouse (Auffray at al., 2009; Mantovani et al., 
2009; Murray et al., 2014). Unfortunately, a gold standard classification of 
phenotype markers is still lacking, although Murray and colleagues (2014) tried to 
address the problem. In particular, the surface markers most commonly used to 
identify classical M1 macrophages are the T-cell co-stimulatory molecules CD80 and 
CD86, and the monocyte chemoattractant protein-1 receptor CCR2, while the 
mannose scavenger receptor CD206 together with CD163 (haemoglobin-
heptoglobin receptor) are often used to identify the M2 subset. More recent 
studies used additional surface markers to better distinguish macrophage subsets. 
In particular, Vogel et al. (2014) investigated novel M1-associated (CD40, CXCL11 
and CCR7) as well as M2-associated (stabilin-1, CD180 and TREM2) cell surface 
markers, and Ambarus and colleagues (2012a) validated specific phenotypic 
markers for in vitro polarized human macrophages, such as CD80 and CD64 for 
IFNγ-activated M1 macrophages and CD200R for IL-4-activated M2a macrophages. 
Gordon and colleagues (2014) suggested CD169 as a new and promising M1 
marker; Martinez et al (2013) performed extensive analysis of mouse and human 
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alternative macrophage activation, and found a set of highly conserved genes that 
were regulated by IL-4 including transglutaminase (TGM)-2. Taken together, these 
findings suggest that any selection of phenotypic markers is certainly non-
exhaustive and strictly dependent to the differentiation protocol as well as the 
activating agents used to induce M1/M2 immunophenotypes.  
We selected CD80 and CCR2 as M1 markers, and CD206, CD163 as markers of the 
M2 immunophenotype. CD80 is a co-regulatory receptor expressed on the surface 
of antigen presenting cells (Dakappagari et al., 2012). Macrophage subpopulations 
have been reported to express high levels of CD80 and CD86; these macrophages 
can present antigens to T cells, thus promoting the inflammatory immune response. 
Jaguin et al. (2013) demonstrated that expression of CD80, which is a strong 
membrane marker of M1 polarization, significantly increased after 24-h LP“/IFNγ 
polarization of M-CSF/CSF-1–differentiated human macrophages. In addition, 
Stöger et al. (2012) demonstrated the prevalence of CD86-expressing M1 
macrophages in atherosclerotic plaques prone to rupture. We observed a significant 
increase in the fraction of CD80
+
 spontaneously differentiated macrophages after 
M1 polarization compared with resting macrophages. These results are in line with 
those of Ambarus and colleagues (2012), who demonstrated the up-regulation of 
CD80 in human macrophages treated with IFN-γ oƌ TNF-α foƌ ϰ oƌ ϳ daǇs staƌtiŶg at 
the beginning of the maturation protocol. CCR2, also known as the receptor for 
MCP-1/CCL2, is widely accepted as an M1 macrophage marker (Mantovani et al., 
2009). Interestingly, it is also expressed on circulating monocytes, and has long 
been used to identify classical/M1 Ly6C
high
 CX3CR1
low
CCR2
+
 monocytes in mice 
(Fadini et al., 2013). We found that the number of CCR2
+
 macrophage was already 
high iŶ the ƌestiŶg state ;MϬͿ aŶd did Ŷot fuƌtheƌ iŶĐƌease afteƌ LP“/IFNγ tƌeatŵeŶt, 
which limited the relevance of CCR2 to our model. Overall, these data suggest that 
24h activation with LPS of CSF-1 differentiated macrophages is able to enhance the 
pro-inflammatory macrophage immunophenotype, specifically by increasing the 
fraction of CD80
+
, CD80
+
/CCR2
+
 cells. The mannose receptor CD206 is a well 
established M2 marker, as well as CD163 (Mantovani et al., 2009; Toniolo et al., 
2014; Vogel et al., 2014; Chinetti-Gbaguidi et al., 2015). When characterizing the 
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M2 immunophenotype, we demonstrated high levels of CD206
+
 and CD163
+
 cells in 
resting conditions. Interestingly, after LPS activation, the percentage of the M2 
immunophenotype significantly decreased independently from the marker used for 
M2 characterization. These results demonstrated that pro-inflammatory stimuli are 
able to enhance the M1 macrophage subset, as well as attenuate the M2 
phenotype. This also indicates that a pro-inflammatory microenvironment causes 
an M2-to-M1 immunophenotype switch and confirms the plasticity of human 
macrophages, which are able to adapt their phenotype and functions according to 
specific microenvironmental signals. Accordingly, studies of adipose tissue 
macrophages in a mildly obese mouse model showed that the M1 subset increases 
concomitantly with a reduction in M2 macrophages, due to enhanced secretion of 
chemoattractant molecules and pro-inflammatory cytokines (Lumeng et al., 2007; 
Kraakman et al., 2014).  
We extended our findings of morphology and macrophage activation as described 
above with data of specific surface marker expression in the human monocyte cell 
line THP-1, in a condition of total absence of CD3
+
 cells. One advantage of using 
macrophage cell lines is increased homogeneity and purity as compared to primary 
cells. THP-1 cells have been proposed as a simplified model to study monocyte–
macrophage polarization (Qin et al., 2012). However, new data redefine tissue 
macrophages as a layered system composed of resident macrophages originating 
mostly from yolk-sac progenitor cells and transitory myeloid cells that originate and 
renew from bone marrow hematopoietic stem cells (Gomez-Perdiguero and 
Geissmann, 2015). Therefore, we and others feel that blood-derived macrophages 
represent a more accurate (and complex) model of macrophage heterogeneity that 
is more suitable to investigate macrophage function in vitro and ex vivo. 
We further defined macrophages subsets after polarization in terms of gene 
expression and cytokine production. Several genes were previously identified as M1 
or M2 markers (Mantovani et al., 2013; Tedesco et al., 2015). The pro-inflammatory 
cytokines TNF-α, IL-6 and IL-ϭβ aƌe ĐƌitiĐal ŵediatoƌs of the aĐute phase ƌespoŶse, 
and are potently induced after LPS or IFN-γ tƌeatŵeŶt. We oďseƌǀed a higheƌ ŵ‘NA 
expression of TNF-α aŶd IL-ϭβ iŶ Mϭ thaŶ iŶ non-polarized (M0) or M2 
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macrophages. In particular, the mRNAs encoding these cytokines accumulated with 
a different time course, e.g. TNF-α ŵ‘NA peaked at ϲh ǁhile IL-ϭβ ƌeaĐhed the 
highest expression level after 48h. It is conceivable that macrophages respond to 
pro-inflammatory stimuli by producing TNF-α, which in turn induces IL-ϭβ geŶe 
expression, thus fortifying the concept that macrophage activation encompasses a 
quantifiable and temporally dynamic process (Tarique et al. 2015). IL-10 was 
previously described as a key marker for the M2 immunophenotype (Mantovani et 
al., 2013) as well as an M2-polarizing agent (Mantovani et al., 2004). Several studies 
are consistent in defining M2 anti-inflammatory macrophages as cells releasing high 
amounts of this cytokine (Mantovani et al., 2013). In addition, differences in IL-10 
expression in lean (higher expression) compared with obese (lower expression) 
mouse adipose tissue macrophages (ATMs) have been reported, thus implying an 
important role of this cytokine as a homeostatic regulator in insulin sensitivity 
(Kammoun et al., 2014). Unexpectedly, we found that IL-10 mRNA levels were 
significantly increased in M1 (LPS) but not in M2 (IL-4/IL-13) activated cells, both 
after 6 and 48 h (Tedesco et al., 2015). Nevertheless, several studies are consistent 
with our findings, demonstrating either increased IL-10 release into the culture 
medium after LPS stimulation (Ambarus et al., 2012b), LPS-induced IL-10 
intracellular accumulation in PBMCs (Muris et al., 2012) or increased IL-10 mRNA 
levels in human M-CSF-generated macrophages after M1 polarization (Jaguin et al., 
2013). We hypothesize that the LPS stimulus is able to induce a typical anti-
inflammatory cytokine, such as IL-10, which probably triggers M2 macrophage 
polarization via more complex and long-term feedback mechanisms. In fact, the 
rapid peak (6h) in IL-10 mRNA levels suggests a possible role of this LPS-responsive 
cytokine in a M1-to-M2 transition involved in the resolution of acute inflammatory 
events (Couper et al., 2008). 
Furthermore, we analyzed cytokines released into the culture medium of M1 and 
M2 activated macrophages by Luminex technology. We looked at the production of 
a panel of 50 cytokines and metabolites in order to correlate the modulation of 
macrophage immunophenotypes with their function. In agreement with mRNA 
expression data, we found increased TNF-α, IL-ϭβ aŶd IL-10 extracellular protein 
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accumulation after incubation with LPS in CSF-1-derived macrophages, in addition 
to IL-6, VEGF and IP-10 (also known as CXCL10 or IFN-γ iŶduĐed pƌoteiŶ-10). M2 
activated macrophages appear to be the most vigorous producers of IL-4 and 
CCL22, also known as macrophage derived chemokine (MDC; Vulcano et al., 2001). 
In agreement with our data, IL-4 and IL-13 have been reported to induce CCL22 
production in monocytes, monocyte-derived macrophages, natural killer (NK) cells 
and DCs (Vulcano et al., 2001). CCL22 expression and secretion was also found to be 
increased in M2 when compared with M0 and M1 macrophages (Jaguin et al., 2013; 
Toniolo et al., 2014). 
The second specific aim of this thesis was to evaluate the impact of curcumin and its 
analogues on macrophage immunophenotypes and function. So far few studies 
addressed if and how specific pharmacological agents affect human macrophage 
immunophenotypes (Bouhlel et al., 2007, Van der Meij et al., 2013). In particular, 
the effects of glucocorticoids were explored in mouse bone marrow-derived 
macrophages (Yang et al., 2012) and in human circulating monocytes (Ehrchen et 
al., 2007; Vallelian et al., 2010). Recently, dexamethasone was shown to induce 
expression of specific human macrophage phenotypic markers according to 
activation protocol and treatment duration including CD163 (Ambarus et al., 2012a; 
Tang et al., 2013). Glucocorticoids have been also found to induce a particular 
mouse macrophages M2 subset, called M2c (Martinez et al., 2008). A recent study 
from our group demonstrate that 17β-estradiol affects macrophage polarization 
and function by preventing LPS effects on the M2 immunophenotype and cytokine 
production (Toniolo et al., 2014). The literature on the potential of natural 
compounds to modulate human macrophage activation and polarization is quite 
limited. In particular, although anti-inflammatory effects of curcumin have been 
reported in a variety of experimental models (Aggarwal and Harikumar, 2009; 
Shehzad et al., 2013), the possibility that curcumin and/or analogues thereof affect 
human macrophage activation has not been explored in much detail. It is worth 
noting that all above studies have been performed in murine macrophages or THP-1 
cell line. We decided to investigate these aspects using dexamethasone and CLI095 
as positive controls using our model of human CSF-1-derived macrophages. 
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It has been shown that curcumin regulates diverse molecular targets implicated in 
inflammation. Specifically, curcumin inhibits inflammatory cytokines such as TNF-α, 
IL-1, IL-6, IL-8, mitogen-activated protein kinase (MAPK), and suppresses inducible 
nitric oxide synthase (iNOS), COX-2 and lipoxygenase (LOX) in a variety of cancer 
cells (Priyanka et al., 2014; Liu et al., 2015). In this regard, our hypothesis is that 
curcumin is mainly acting as an inhibitor of LPS activation, especially on the 
expression of M1 markers (such as CD80) that are modulated via the NF-κB pathǁaǇ 
(Lien and Golembock, 2003). Our data clearly show that the curcumin analogue GG9 
was able to prevent the up-regulation of CD80 expression induced by LPS activation 
(Fig. 4.12 panel A and B), thereby modulating M1 polarization. This effect was also 
observed for the CD80
+
/CCR2
+
 population, although statistical significance was not 
achieved. In the literature curcumin is reported to affect M2 activation: in 
particular, Chen and colleagues (2014) showed that curcumin not only directly 
induces the polarization of macrophages to M2 phenotype, but also promotes a 
switch from M1 to M2 phenotype in RAW264.7 macrophages. More recently, Gao 
et al. (2015) demonstrated that curcumin induces M2 polarization of RAW264.7 
cells by increasing the production of IL-4 and/or IL-13 in a STAT6-dependent 
manner. In our model of CSF-1-derived human macrophages, treatment with GG9 
significantly prevented LPS-induced down-regulation of M2 markers, thereby acting 
as an anti-iŶflaŵŵatoƌǇ ageŶt. IŶ ĐoŶtƌast ǁith Gao͛s ǁoƌk aďoǀe, Ŷo effeĐt oŶ the 
M2 markers could be seen with GG9 alone, while dexamethasone treatment in M0 
or activated M2 macrophages enhanced CD206
+
/CD163
+
 macrophage subsets, 
consistently with findings from different experimental models (Fig. 4.14; Ambarus 
et al., 2012b; Heasman et al., 2004, Tang et al. 2013; Tedesco et al., 2014).  
The LPS-induced production of inflammatory mediators is linked to a series of 
intracellular signaling pathways ultimately resulting in activation of NF-κB, ǁhiĐh 
regulates the expression of a variety of target genes, including those encoding 
cytokines. Singh and Aggarwal (1995) were the first to demonstrate that curcumin is 
a potent blocker of NF-κB aĐtiǀatioŶ iŶduĐed ďǇ diffeƌeŶt iŶflaŵŵatoƌǇ stiŵuli. 
Subsequently, they showed that curcumin blocks NF-κB aĐtiǀatioŶ thƌough 
iŶhiďitioŶ of IκB-α kiŶase and Akt (Aggarwal et al., 2005), thus resulting in the 
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suppression of NF-κB–dependent gene products (Aggarwal and Harikumar, 2009). 
More recently other studies showed that NF-κB ŶuĐleaƌ tƌaŶsloĐatioŶ is mediated at 
least in part by direct inhibition of expression and/or activation of TLR2 or TLR4, or 
their associated signaling proteins (Youn et al., 2006; Lubbad et al., 2009; Zhou et 
al., 2015; Wang et al., 2015). In particular, Youn et al. (2006) described in detail the 
molecular mechanisms by which curcumin acts on NF-κB pathǁaǇ: the ĐoŵpouŶd 
inhibits LPS-iŶduĐed TL‘ϰ diŵeƌizatioŶ, aŶd its α,β-unsaturated carbonyl group can 
react with –SH group in cysteine in the activation loop of IKK-β, ƌesultiŶg iŶ 
inhiďitioŶ of IKKβ kiŶase aĐtiǀitǇ. Gƌadisaƌ aŶd Đolleagues ;ϮϬϬϳͿ pƌoposed a 
different interaction: within its structure, curcumin binds at submicromolar affinity 
through its 3-(4-hydroxyphenyl) acrylaldehyde moiety to MD2, a protein that 
associates with TLR4 and confers responsiveness to LPS, thus providing a link 
between the receptor and LPS signaling. According to Gradinsar, curcumin may 
compete with LPS for the same binding site on MD2, thus resulting in the 
pharmacological outcomes of suppression of LPS inflammatory cascade. More 
recently, Zhou et al. (2015) also described that the turmeric compound decreased 
TLR4 expression. In particular they found out that TLR4 small interfering RNA 
transfection in combination with p-JNK, p-ERK, and p-p38 inhibition reduced the 
effect of curcumin on the polarization of THP1-derived macrophages (Zhou et al., 
2015). Furthermore, Buhrmann et al. (2011) demonstrated that curcumin 
suppresses IL-ϭβ-induced NF-κB aĐtiǀatioŶ aŶd ŶuĐleaƌ tƌaŶsloĐatioŶ as ǁell as IL-ϭβ 
induced phosphatidylinositol 3-kinase (PI3K/Akt) activation through decreased 
phosphoƌǇlatioŶ aŶd degƌadatioŶ of IκB-α. We assessed ǁhetheƌ ĐuƌĐuŵiŶ 
aŶalogues ŵodulated IκB-α eǆpƌessioŶ pƌofiles as aŶ iŶdeǆ of NF-κB aĐtiǀatioŶ iŶ 
our model (Fig. 4.15). The curcumin analogue GG9 did not alter IκB-α protein level 
with respect to LPS whereas treatment with curcumin, GG6 or CLI095 significantly 
prevented NF-κB aĐtiǀatioŶ. Moƌe eǆpeƌiŵeŶts aƌe ƌeƋuiƌed to fuƌtheƌ iŶǀestigate 
the effect of GG9, which appears to interfere with the NF-κB pathǁaǇ. Recently 
Mercanti et al. (2014) demonstrated that non-cytotoxic concentrations of 
phosphatidylserine and curcumin significantly inhibit the LPS-induced release of 
pro-inflammatory IL-ϭβ, IL-6 and TNF-α iŶ pƌiŵaƌǇ ƌat ŵiĐƌoglia. As for studies in 
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human cell systems, Abe et al. (1999) first demonstrated that curcumin inhibits 
inflammatory cytokines production in human peripheral blood monocytes.  
In order to evaluate whether curcumin affects human monocyte-macrophage 
function along with immunophenotypes, we invesigated the effects of GG9 on 
cytokine production in CSF-1-derived macrophages (Fig. 4.16 and 4.17). 
Dexamethasone and CLI095 were again used as positive controls. GG9 appeared to 
be active on both cell-bound and intra-/extracellular IL-ϭβ, as this ĐuƌĐuŵiŶ 
analogue was able to significantly block cell-bound IL-ϭβ pƌoduĐtioŶ as ǁell as that 
in cell lysate and in the culture medium. By contrast, curcumin and GG6 did not 
affect the levels of intra- and extracellular IL-ϭβ, suggestiŶg a different interaction 
of those molecules with the receptor at a structural level. It is important to 
underline that IL-ϭβ pƌoduĐtioŶ ďǇ C“F-1–derived macrophages was very difficult to 
assess because IL-ϭβ oĐĐuƌs iŶ Đells at tǁo diffeƌeŶt stages of ŵaturation: pro-IL-ϭβ 
and IL-ϭβ ;Feƌƌaƌi et al., ϭϵϵϳͿ. Seen that the antibodies used are able to bind both 
forms, the experimental set up was complicated. As a potential future research 
question, it would be interesting to investigate how curcumin and its analogues 
modulate the release of other cytokines, both with pro-inflammatory (TNF-αͿ aŶd 
anti-inflammatory (IL-10, CCL22, IL-4) activity, and if or how long-term stimulation 
(3-7 days) affect macrophage M2 polarization, thus acting like dexamethasone or E2 
(Tedesco et al., 2015; Toniolo et al., 2014). 
Taken together, these results provide the basis to support the central hypothesis of 
this project that natural compounds could affect monocyte-macrophage 
immunophenotypes, in particular by acting on LPS activation through NF-κB 
pathway. We found that curcumin analogues were able to prevent the down-
regulation of M2 markers and the up-regulation of M1 markers, and to block 
secretion of the pro-inflammatory cytokine IL-ϭβ folloǁiŶg LP“ aĐtiǀatioŶ, 
suggesting that these compounds impact on macrophage function in vitro. On a 
molecular level, in agreement with previous studies, curcumin analogues are able to 
block the NF-κB sigŶaliŶg pathǁaǇ, pƌoďaďlǇ aĐtiŶg at diffeƌeŶt leǀels oŶ TL‘ϰ-MD2 
iŶteƌaĐtioŶ aŶd IKKβ kiŶase aĐtiǀitǇ ;YouŶ et al., ϮϬϬϲ; Gƌadisaƌ et al., ϮϬϬϳͿ.  
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The possibility to promote a macrophage protective phenotype has become a 
therapeutic goal in the treatment of inflammatory conditions, and the identification 
of factors that control cell activation is currently an area of active research. Overall, 
this projeĐt͛s output suggests that polaƌized aĐtiǀatioŶ pƌotoĐols shape the 
functional status of macrophages and are critical to investigate pharmacological 
macrophage targeting. The present findings suggest that curcumin and its 
analogues represent promising lead compounds targeting immune cells activation. 
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